

TRADE NAMES

Trade names for the most frequently prescribed drugs (top 200 drugs) are shown in CAPITAL LETTERS.

MAJOR CITATION

Page numbers shown in **bold** indicate the location of the most extensive discussion of the drug or topic.

Acetaminophen (TYLENOL), 401*f*, 412, **412-413**

CITATION IN FIGURES

Page number followed by "f" indicates information about the drug appears in a figure.

PRONUNCIATION

Page number in *italics* indicates location of pronunciation of drug.

Information
contained
in this

Index

"See" cross-references direct the reader to the synonymous term. "See also" cross-references direct the reader to related topics. [Note: Positional and configurational designations in chemical names (for example, "3-", "α-", "N-", "D-") are ignored in alphabetizing.]

Abortion, drugs for, 419

Absence seizures, **144**, 144*f*-145*f*
treatment, 149

Absorption, drug, 1, 1*f*, **4-6**

Abstinence, percent use, 268*f*

Acarbose, **261**, 261*f*

ACCUPRIL. *See* Ramipril

Acebutolol, 71*f*, **77**, 77, 79*f*
actions, 75*f*

clinical applications, 78*f*

contraindication, 177

drug elimination, 74*f*

Acetaminophen (TYLENOL), 401*f*, 412,
412-413

actions, 405*f*

drug interactions, 140

metabolism, 413*f*

for migraine, 428

for Reye's syndrome, 407

Acetazolamide, 223*f*, **226-227**

and changes in urine composition, 226*f*,
233*f*

drug interactions, 292

for glaucoma, 41

site of action, 224*f*

Acetohexamide, 255*f*, 260, 260

properties, 261*f*

Acetylcholine, 35*f*, 39, **39-40**

binding, 36-37, 37*f*

degradation, 37, 37*f*

drug interactions, 236

interaction with membrane receptors, 21

and muscarinic receptor, 46*f*

as neurotransmitter, 32*f*, 33

release, 36, 37*f*

sites of action, 36*f*

storage, 35, 37*f*

structure, 39*f*

synthesis, 35, 37*f*

Acquired immunodeficiency syndrome
(AIDS), treatment, **368-371**

ACTH. *See* Corticotropin

Actinomycetes, 290*f*

Actinomycin D. *See* Dactinomycin

Activated attapulgite, 244, 244*f*

Acycloguanosine. *See* Acyclovir

Acyclovir (ZOVIRAX), 363*f*, 365, **365-366**

mechanism of action, 365, 366*f*

survival rate with, 367*f*

Acylureido penicillins, 301

drug elimination, 303

ADALAT. *See* Nifedipine

Addison's disease, treatment, 274

Adenosine, 163*f*, **174**

antiarrhythmic effects, 164*f*

Administration routes, drug, **1-4**, 2*f*

Adrenal androgens, production, 272

Adrenal corticosteroids, **272-277**

drug interactions, 270

inhibitors, 277

therapeutic uses, 274-276

β-Adrenergic agents, for chronic
obstructive pulmonary disease, 222

Adrenergic agonists, **55-70**

adverse effects, 68*f*

for asthma, 218, 218*f*

characteristics, 59-61

direct-acting, **61-67**

mechanism of action, 61

sites of action, 62*f*

indirect-acting, **67-68**

mechanism of action, 61

sites of action, 62*f*

mechanism of action, 61

mixed-action, **68-69**

mechanism of action, 61

sites of action, 62*f*

sites of action, 56*f*, 62*f*

specific agents, 55*f*

structures, 61*f*

summary, 69*f*

β-Adrenergic agonists, 151*f*

for asthma, 217*f*

for chronic obstructive pulmonary
disease, 217*f*

for congestive heart failure, 161

sites of action, 161*f*

α-Adrenergic agonists, for rhinitis, 221

specific agents, 217*f*

Adrenergic agonists, specific agents

albuterol, 55*f*, 67*f*, 69*f*, 218, 431-432,
441

clonidine, 55*f*, **67**, 67, 69*f*, 180*f*, 189,
189-190, 442

dobutamine, 55*f*, **66**, 66, 69*f*, 151*f*, 159,
161, 161*f*

dopamine, 55*f*, 56, 61*f*, 65, **65-66**, 66*f*,
69*f*, 161*f*, 248*f*

epinephrine, 3, 32*f*, **33**, 40-41, 55*f*, 58*f*,
58-59, 60*f*, 61, 61, 61*f*, **61-63**, 63*f*,
67*f*, 69*f*, 72, 72*f*, 118, 164*f*, 218, 424

isoproterenol, 55*f*, 58, 58*f*, 61, 61*f*, 64,
64-65, 65*f*-67*f*, 69*f*, 72*f*, 75

metaproterenol, 55*f*, **67**, 67, 67*f*, 69*f*

- methoxamine, 55*f*, 66, **66-67**, 69*f*
 norepinephrine, 32*f*, **33**, 36*f*, 55, 55*f*, 56, 57*f*-58*f*, 58-59, 61, 61*f*, 64, **64**, 64*f*, 69*f*, 72*f*, 78-79
 phenylephrine, 47, 55*f*, 58, 60, 60*f*, 61, 66, **66**, 69*f*, 113, 221
 ritodrine, 55*f*, 69*f*
 terbutaline, 55*f*, 62-63, 67, **67**, 67*f*, 69*f*, 218
- Adrenergic blockers, 71-80**
 α -Adrenergic blockers, 58, 58*f*-59*f*, 71-73
 adverse effects, 73*f*
 blood pressure and, 72*f*
 effects, 60*f*
 for hypertension, **189**
 specific agents, 71*f*, 180*f*
- β -Adrenergic blockers, 58*f*, 58-59, 73-78, 163*f*, 419*f*, 436, 442**
 actions, 60*f*, 75*f*
 adverse effects, 79*f*
 for angina, 176-177
 specific agents, 175*f*
 treatment with concomitant diseases, 178*f*
 clinical applications, 78*f*
 contraindications, 185
 drug interactions, 188*f*, 409
 elimination, 74*f*
 for hypertension, **184-187**
 actions, 184*f*
 adverse effects, 185, 185*f*
 with concomitant diseases, 182*f*
 specific agents, 179*f*
 for migraine, 427*f*, 428
 summary, 79*f*
- Adrenergic blockers, specific agents, 71*f***
 acebutolol, 71*f*, 74*f*-75*f*, 77, **77**, 78*f*-79*f*, 177
 atenolol, 71*f*, 75*f*, 77, **77**, 79*f*, 176, 179*f*, 185
 doxazosin, 71*f*, **73**, 73, 180*f*
 labetalol, 71*f*, 74*f*, 78, **78**, 79*f*, 179*f*, 191
 metoprolol, 71*f*, 74*f*-75*f*, 77, **77**, 78*f*-79*f*, 171, 176, 179*f*, 185
 nadolol, 71*f*, 74*f*, 76, **76**, 78*f*, 179*f*, 428
 phenoxybenzamine, 71, 71*f*, **71-72**, 72*f*
 phentolamine, 71*f*, **72**, 72, 124
 pindolol, 71*f*, 74*f*, 77, **77**, 79*f*, 171, 177
 prazosin, 71*f*, **73**, 73, 124, 180*f*, 189
 propranolol, 7, 71*f*, 74, 74*f*, **74-76**, 75*f*-76*f*, 78*f*-79*f*, 163*f*-164*f*, 171, 175*f*, 176, 179*f*, 185, 190, 334*f*, 427*f*, 428, 436-437
 terazosin, 71*f*, **73**, 73, 180*f*, 189
 timolol, 71*f*, 74*f*, 76, **76**, 78*f*-79*f*, 179*f*
- β -Adrenergic blockers, specific agents, 71*f***
 Adrenergic, definition, **33**
 Adrenergic neuron, **55-59**
 Adrenergic receptors (adrenoceptors), **57-59**
 types, 58*f*
 Adrenocortical insufficiency
 primary, treatment, 274
 secondary, treatment, 274
 tertiary, treatment, 274
 treatment, 274
 Adrenocorticotrophic hormone. *See* Corticotropin
 ADRIAMYCIN. *See* Doxorubicin
 Adsorbent agents, 244
 ADVIL. *See* Ibuprofen
 Afferent neuron, **28**
 African sleeping sickness, 353
 Agar, 245
 Agonists. *See also* β -Adrenergic agonists; Adrenergic agonists; α -Adrenergic agonists
 cholinergic, **35-44**, 36*f*. *See also* **Cholinergic agonists, specific agents**
 adverse effects, 49*f*
 antidote for, 47
 indirect, 41, 42*f*
 reversible, 41, 42*f*
 sites of action, 36*f*
 structures, 39*f*
 indirect-acting, 61
 opioid
 actions, 134*f*
 adverse effects, 137*f*
 moderate, **140**
 onset and duration of action, 139*f*
 strong, **135-140**
- AIDS. *See* Acquired immunodeficiency syndrome
- Albumin
 binding capacity, 11
 drug binding to, 11-12, 12*f*
- Albuterol (VENTOLIN, PROVENTIL), 55*f*, 69*f*, 431-432, 441
 for asthma, 218
 and bronchodilation, 67*f*
- ALDOMET. *See* Methyldopa
- Aldosterone, production, 272, 272*f*
- Alkylamines, therapeutic advantages and disadvantages, 422*f*
- Alkylating agents
 actions, 374*f*
 in cancer therapy, **387-390**
 specific agents, 373*f*
- Allergic conjunctivitis, treatment, 411
 Allergic rhinitis, treatment, 276, 424
 Allergies, treatment, 276, 423-424, 438-439
- Allopurinol, 402*f*, 416, **416-417**
 drug interactions, 260*f*, 382
 for hyperuricemia, 415
 for leishmaniasis, 356
- Aloe, 244, 244*f*
- Alprazolam (XANAX), 90, 242*f*, 438
 adverse effects of, 94*f*
 for chemotherapy-induced nausea and vomiting, 243
 duration of action, 92*f*
 for panic disorders, 90
 therapeutic advantages and disadvantages, 97*f*
 withdrawal reactions, 93*f*
- Alprostadil, for erectile dysfunction, 420
- ALTACE. *See* Ramipril
- Alteplase (tPA), 193*f*, 201, 202, **202**
 activation of plasminogen, 202*f*
 properties, 202*f*
- Aluminum acetate, 438
 Aluminum hydroxide, 236*f*, 240, 439-441
 Alveolar wash-in, 111
- Amantadine, 81*f*, **87**, 87, 363, 363*f*, **363-364**, 364*f*
- AMBIEN. *See* Zolpidem
- Amebiasis
 chemotherapy, 345*f*, **345-348**
 extraintestinal, treatment, 351
- Amebic dysentery. *See* Amebiasis
- Amebicides
 luminal, 346, **348**
 sites of action, 346*f*
 mixed, 346, **347-348**
 sites of action, 346*f*
 systemic, 346, **348**
 sites of action, 346*f*
- American sleeping sickness. *See* Chagas' disease
- Amikacin, 311*f*, 315, 315, 433
 adverse effects, 316
 therapeutic applications, 315*f*
- Amiloride, 223*f*, **233**, 233
 site of action, 224*f*
- Amine nitrogen, substitution on, 61
- γ -Aminobutyric acid, binding, 89-90, 91*f*
- Aminocaproic acid, 193*f*, **204**, 204
- Aminoglutethimide, **277**, 277, 373*f*
 in cancer therapy, 395, 395
- Aminoglycosides, **314-317**

- adverse effects, 316-317, 317f
classification, 287f
drug interactions, 51, 338
penicillins and, 301
resistance to, 285f
for urinary tract infections, 328f
- Aminoglycosides, specific agents, 311f**
amikacin, 311f, 315, 315f, 316, 433
gentamicin, 51, 311f, 315, 315f, 316, 435
neomycin, 311f, 316, 316f, 317
netilmicin, 311f, 316, 316f
streptomycin, 311f, 314, 314f, 315, 315f, 331
tobramycin (TOBREX), 51, 311f, 315, 315f, 316, 316f, 431
- p*-Aminomethylbenzenesulfonamide, for burns, 291
- 5-Aminosalicylate, in inflammatory bowel disease, 291
- Aminosalicylic acid, 331f, 335, 335f
- Amiodarone, 163f, 172, 172f
antiarrhythmic effects, 164f
drug interactions, 160f
- Amitriptyline (ELAVIL), 96, 119, 119f, 119f
therapeutic advantages and disadvantages, 125f
- Amlodipine (NORVASC), 180f, 188, 188f
for angina, 188f
for congestive heart failure, 157, 188f
drug interactions, 188f
for hypertension, 188f
- Amobarbital, 90f, 94
duration of action, 95
therapeutic advantages and disadvantages, 97f
- Amoxapine, 119, 119f, 119f
therapeutic advantages and disadvantages, 125f
- Amoxicillin (AMOXIL, POLYMOX, TRIMOX, WYMOX), 235f, 298f, 300, 300f
absorption, 302
administration route, 302
cost, 282, 282f
drug interactions, 308, 308f
to eliminate *Helicobacter pylori*, 236
stability
to acid, 300f
to penicillinase, 300f
for urinary tract infections, 328f
- AMOXIL. *See* Amoxicillin
- Amphetamines, 55f, 67, 67-68, 69f, 99f, 103-104
adverse effects, 105
dependence potential, 100f
drug interactions, 138
as indirect-acting agonist, 61
mechanism of action, 104f
non-catecholamine, 60
- Amphotericin B, 337, 337f, 337-339, 338f
for cryptococcal meningitis, 284f
drug interactions, 339-340
for leishmaniasis, 356
- Ampicillin (PRINCIPEN), 298f, 300, 300, 435
administration route, 302
as chemotherapeutic agent, 283
for listeriosis, 299f
stability
to acid, 300f
to penicillinase, 300f
therapeutic applications, 290, 301
for urinary tract infections, 328f
- Amrinone, 151f, 161, 161f, 161f
- Anabolic steroids, 270
adverse effects, 271
- Analgesic(s)
for migraine, 427f, 428
morphine as, 137
non-narcotic, 411-413
specific agents, 401f
salicylates as, 404, 406
- Anaphylactic shock, treatment, 62-63
- Anaphylaxis, acute, treatment, 218
- ANAPROX. *See* Naproxen
- Ancylostoma duodenale* infection, 361f
treatment, 359
- Androgenic steroids, 270
- Androgens, 269-272
- Androgens, specific agents, 263f**
danazol, 263f, 270, 270f, 271
fluoxymesterone, 263f, 271, 271f
nandrolone, 263f, 271, 271f
stanozolol, 263f, 271, 271f
testosterone cypionate, 263f, 271, 271f
- Anemia
megaloblastic, and folate deficiency, 205
treatment, 205-206
specific agents, 193f
- Anesthesia, 107-118
adjuncts to, specific agents, 107f
components, 109f
induction, 109
maintenance, 109
patient selection for, 107-108
recovery, 109
stages, 110, 110f
- Anesthetics
barbiturates as, 95
cocaine as, 102
epinephrine in, 63
inhalation, 110-115
changes in alveolar blood concentrations, 112f
therapeutic advantages and disadvantages, 116f
intravenous, 115-117
therapeutic advantages and disadvantages, 116f
uptake, 111-112
uptake curves, 112, 112f
vapor (gas), minimal alveolar concentrations (MAC), 111, 111f
- Anesthetics, specific agents, 107f-108f**
- Angina pectoris
with concomitant diseases, treatment, 178f
with hypertension, 182f-183f, 185
treatment, 73, 75, 77, 78f, 173, 175-178, 187, 188f, 189, 196, 204-206, 406
- Angiotensin converting enzyme inhibitors, 151f, 156-157, 442
drug interactions, 409
effects, 156f
for hypertension, 186-187
actions, 186, 186f
adverse effects, 186f, 186-187
with concomitant diseases, 182f
specific agents, 179f
- Angiotensin II antagonists, for hypertension, 187
specific agents, 179f
- Anisoylated plasminogen streptokinase activator complex. *See* Anistreplase
- Anistreplase, 193f, 203, 203f
properties, 202f
- Ankylosing spondylitis, treatment, 409-411
- Anorexia nervosa, treatment, 122
- ANSAID. *See* Flurbiprofen
- Antacids
drug interactions, 408f
for peptic ulcer disease, 236f, 240
- Antagonists, 22f
angiotensin II, for hypertension, 187
specific agents, 179f
benzodiazepine, 94
specific agents, 90f
cholinergic, 45-54
for asthma, 220
sites of action, 46f

- specific agents, 45f
summary, 49f
- folate, **289-296**
specific agents, 289f
- histamine H₂-receptor, 440
- opioid, **133-142, 141-142**
actions, 134f
specific agents, 133f
- reversible, 22
- serotonin, antiemetic potency, 243f
- steroid, for cancer, 392-395
specific agents, 373f
- Anterior pituitary hormones, 247f, **247-250**
actions, 248f
- Anthelmintic drugs, **359-362**
specific agents, 359f
- Antiandrogens, **272**
- Antiandrogens, specific agents**
cyproterone acetate, 272, 272
finasteride, 73, 272, 272
flutamide, 272, 272, 373f, 394, 394-395, 399f
- Antianginal drugs, **175-178**
- Antianginal drugs, specific agents,**
175f
- diltiazem (CARDIZEM CD, DILACOR XR), 163f, **173, 173, 173f, 175f, 177, 177, 180f, 187, 187, 187f-188f**
- isosorbide dinitrate, **157, 175f, 176, 176, 177f**
- nifedipine (ADALAT, PROCARDIA XL), 173, 173f, 175f, 177, **177, 187, 187f, 187-188, 188f**
- nitroglycerin (NITROSTAT), 2, 4, 175f, **175-176, 176, 177f, 442**
- propranolol (INDERAL), 7, 71f, 74, 74f, **74-76, 75f-76f, 78f-79f, 163f-164f, 171, 175f, 176, 179f, 185, 190, 334f, 427f, 428, 436-437**
- verapamil (ISOPTIN, VERELAN), 160f, 163f-164f, 167, 169, **173, 173, 173f, 175f, 177, 177, 180f, 187, 187, 187f-188f, 189, 377**
- Antianxiety drugs, specific agents**
alprazolam (XANAX), 90, 90, 92f-94f, 97f, 242f, 243, 438
- bupirone (BUSPAR), **93, 93, 94f, 97f**
- chlordiazepoxide, 91, 92f, 97f
- clonazepam (KLONOPIN), 91, 91, 97f, 143f, 145f, 149
- clorazepate (TRANXENE), 91, 91, 92f, 97f, 143f, 149
- diazepam (VALIUM), 50, 90, 90, 90f, 91, 91, 92f-93f, 97f, 103, 108, 108f, 116, 143f, 145f, 149, 239
- estazolam, 92f
- flurazepam, 91, 91, 92, 92f-93f, 97f, 137
- hydroxyzine, **93, 93, 97f, 138, 422f**
- lorazepam (ATIVAN), 92f-93f, 97f, 108f, 116, 242f, 243, 243f
- midazolam, 97f, 108f, 116
- quazepam, 92f-93f, 97f
- temazepam (RESTORIL), 91, 92, 92f-93f, 97f
- triazolam (HALCION), 91, 92, 92f-93f, 97f
- zolpidem (AMBIEN), **93, 93, 97f**
- Antiarrhythmic drugs, specific agents**
adenosine, 163f-164f, **174**
- amiodarone, 160f, 163f-164f, 172, **172**
- bretium, 163f-164f, 172, **172**
- digoxin (LANOXIN), 151f, 156, 158, 158, 159, 160f, 163f-164f, 169, 174, 177, 188, 213, 320, 352, 395, 410, 439-441
- diltiazem (CARDIZEM CD, DILACOR XR), 163f, **173, 173, 173f, 175f, 177, 177, 180f, 187, 187, 187f-188f**
- disopyramide, 167f, **169, 169**
- disopyramide (IA), 163f
- esmolol, 74f, **77, 77, 78f, 163f, 171, 171**
- flecainide, **170, 170, 170f**
- flecainide (IC), 163f
- lidocaine, 3, 7, 108f, 117f, 164f, 169, **169, 169f, 174**
- lidocaine (IB), 163f
- metoprolol and pindolol, 163f
- mexiletine, 147, 169f, **170, 170, 171, 172f**
- mexiletine (IB), 163f
- procainamide, 167f, **168, 168, 171, 172f**
- procainamide (IA), 163f
- propafenone, **170, 170, 170f, 171, 172f**
- propafenone (IC), 163f
- propranolol (INDERAL), 7, 71f, 74, 74f, **74-76, 75f-76f, 78f-79f, 163f-164f, 171, 175f, 176, 179f, 185, 190, 334f, 427f, 428, 436-437**
- quinidine, 147, 160f, 164f, 167, 167f, **167-168, 169, 171, 172f, 214, 334f, 345f**
- quinidine (IA), 163f
- quinidine sulfate, 168
- sotalol, 163f-164f, 171, **171-172, 214**
- tocainide, 169f, **170, 170**
- tocainide (IB), 163f
- verapamil (ISOPTIN, VERELAN), 160f, 163f-164f, 167, 169, **173, 173, 173f, 175f, 177, 177, 180f, 187, 187, 187f-188f, 189, 377**
- Antiarrhythmics, 163-174, 164f**
class I, 163f, **166-170**
class II, 163f, **170-171**
class III, 163f, 171f, **171-172**
- class IV, 163f, **173**
effects, 173f
long-term effects, 166, 166f
- Antiarrhythmics, specific agents, 163f**
- Antiarthritis drugs, specific agents, 402f**
chloroquine, 345f-346f, 350, 350f, 351, **351-352, 352, 352f, 402f, 414**
- chloroquine phosphate, 432-433
- gold salts, 402f, **413-414**
- methotrexate, 205, 241f, 292-293, 295, 373f-374f, 378, 378, 378f, **378-380, 379f, 384, 399f, 402f, 410, 415, 415, 419**
- D-Penicillamine, 402f, **414, 414**
- Antibiotics. *See also* Antimicrobial agents; *specific agent*
for cancer, **384-387**
specific agents, 373f
complications, 286
- Anticancer drugs, **373-400**
adverse effects, 399f
emetic potential, 241f
- Anticancer drugs, specific agents, 373f**
asparaginase, 241f
- bleomycin, 241f, 373f, 378, 378f, 386, **386-387, 387f, 395, 399f**
- carboplatin, 241f, 373f, 378f, 395, 395-396
- carmustine, 241f, 373f, 389, **389-390**
- cisplatin, 241f, 242-243, 316, 373f-374f, 387, 395, 395-396, 399f
- cyclophosphamide, 241f, 373f, 378f, 388, **388-389, 389f, 395, 399f**
- cytarabine, 373f-374f, 378f, 383, **383-384, 399f**
- dactinomycin, 21, 241f, 373f-374f, 377, 384, **384-385, 399f**
- daunorubicin, 373f-374f, 382, 385, **385-386**
- doxorubicin, 241f, 242, 373f-374f, 378, 378f, 385, 385f, **385-386, 399f, 429**
- estrogens (PREMARIN), 263, **263-266, 266, 266f, 268, 268f, 373f, 394, 399f**
- etoposide, 241f, 373f, 378f, 386, 396, **396, 397f, 399f**
- fludarabine, 373f, **384, 384**
- 5-fluorouracil, 373f-374f, 378f, 382, **382-383, 383f, 399f**
- flutamide, 272, 272, 373f, 394, 394-395, 399f
- goserelin, 247f, 250, 250, 373f, 394, 394, 395, 395f
- goserelin acetate, 394
- idarubicin, 373f, 385
- ifosfamide, 373f, 388, **388-389, 389f**
- interferons, 363f, **371, 371, 371f, 373f, 397-398, 399f**

- leuprolide, 247f, 250, 250, 373f, 394, 394, 395, 395f, 399f
- mechlorethamine, 241f, 373f, 387, **387-388**, 388f, 399f
- 6-mercaptopurine, 373f-374f, 380, **380-381**, 381f, 399f, 417
- navelbine, 373f
- paclitaxel, 373f, 391, **391-392**, 392f, 399f
- plicamycin, 373f, 387, **387**, 399f
- prednisone (DELTASONE, ORASONE), 219, 275f, 276, 334f, 373f, **393**, 393, 397, 399f, 438-439
- procabazine, 373f, 378f, 396, **396-397**, 399f
- streptozocin, 241f
- tamoxifen (NOLVADEX), 263f, **266**, 266, 373f, 393, **393-394**, 399f
- 6-thioguanine, 373f, 382, **382**, 399f
- vinblastine, 373f, 378f, 386, 390, **390-391**, 395, 399f
- vincristine, 241f, 373f, 378f, 384, 390, **390-391**, 397, 399f
- Anticholinergics**, 107f
- antiemetic potency, 243f
 - for chronic obstructive pulmonary disease, 222
 - preanesthetic, 108
- Anticholinergics, specific agents**
- atropine (DONNATAL), 4, 40-41, 41f, 42-43, 45, 45f, **45-48**, 46f, 49f, 64, 220, 220f
 - ipratropium (ATROVENT), 45f, **48**, 48, 49f, 217f, 220, 220, 220f, 222
 - scopolamine, 45f-46f, 48, **48**, 48, 48f-49f, 108, 129f, 130, 242, 438
- Anticholinesterases**
- irreversible, **43**
 - reversible, **41-43**
- Anticoagulants**, **197-201**
- for atrial fibrillation, 164f
 - drug interactions, 147
- Anticoagulants, specific agents**, 193f
- enoxaprin, 193f, 198-199, 199
 - heparin, 193f, **197-199**, 198, 198f, 199, 204, 339, 408f
 - warfarin (COUMADIN), 22f, 22-23, 188, 193f, 196, 199, **199-201**, 200, 200f-201f, 213, 239, 292, 295, 320, 326, 334f, 341, 411
- Anticonvulsive drugs. See also Antiepileptic drugs**
- barbiturates as, 95
 - therapeutic indications, 145f
- Antidepressants**, 90f, 96, **119-126**
- onset, 121f
 - polycyclic. *See Polycyclic antidepressants*
 - receptor specificity, 121f
 - therapeutic advantages and disadvantages, 125f
 - tricyclic. *See Tricyclic antidepressants*
- Antidepressants, specific agents**, 119f
- amitriptyline (ELAVIL), 96, 119, 119, 119f, 125f
 - amoxapine, 119, 119, 119f, 125f
 - desipramine, 119, 119, 119f, 125f
 - doxepin, 96, 119, 119, 119f, 125f
 - fluoxetine (PROZAC), 119f, 121f, 122, 122f, **122-123**, 123f, 125f
 - fluvoxamine, 119f, 123, 123, 125f
 - imipramine, 56, 119, 119, 119f, 120-121, 121f, 125f, 171, 172f
 - isocarboxazid, 119f, 123, 123, 125f
 - lithium salts, **125**
 - maprotiline, 119, 119, 119f, 125f
 - nefazodone, 119f, 123, 123, 125f
 - nortriptyline (PAMELOR), 119, 119, 119f, 125f
 - paroxetine (PAXIL), 119f, 123, 123, 125f
 - phenelzine, 86, 119f, 123, 123, 125f
 - protriptyline, 119, 119, 119f, 125f
 - sertraline (ZOLOFT), 119f, 123, 123, 125f
 - tranylcypromine, 119f, 123, 123, 125f
 - trazodone, 96, 119f, 123, 123, 125f
 - trimipramine, 119f, 125f
 - venlafaxine, 119f, 123, 123, 125f
- Antidiarrheal agents**, **243-244**
- specific agents, 244f
- Antidiuretic hormone**, **251**
- Antiemetic agents**, 107f, 129f, 242-243
- administration route, 2
 - potency, 243f
 - preanesthetic, 108
- Antiemetic drugs, specific agents**
- alprazolam (XANAX), 90, 90, 92f-94f, 97f, 242f, 243, 438
 - dexamethasone, 235, 242f, 243, 243f, 275f-276f, 277, 362, 392, 395
 - domperidone, 129f, 242f, 242-243
 - dronabinol, **105**, 105, 242f, 243, 243
 - droperidol, 108, 117, 129f, 130, 130, 139, 242f, 242-243, 243f
 - granisetron, 242f, 243, 243
 - haloperidol, 84, 105, 127, 127, 127f-129f, 130-131, 131f-132f, 242f, 242-243
 - haloperidol decanoate, 3, 130
 - lorazepam (ATIVAN), 92f-93f, 97f, 108f, 116, 242f, 243, 243f
 - methylprednisolone, 219, 242f, 243, 275f-276f
 - metoclopramide (REGLAN), 129f, 242, 242, 242f, 242-243, 243f
 - nabilone, 242f, 243
 - ondansetron, 242f, 243, 243, 243f
 - prochlorperazine (COMPazine), 127f, 129, 129f, 242, 242, 242f, 243
- Antiepileptic drugs**, **145-150. See also Anticonvulsive drugs**
- drug interactions, 147
 - mechanism of action, 145
- Antiepileptic drugs, specific agents**, 143f
- carbamazepine (TEGRETOL), 143f, 145f, 147, 147, 147f-148f, 150, 319-320, 362
 - clonazepam (KLONOPIN), 91, 91, 97f, 143f, 145f, 149
 - clorazepate (TRANXENE), 91, 91, 92f, 97f, 143f, 149
 - diazepam (VALIUM), 50, 90, 90, 90f, 91, 91, 92f-93f, 97f, 103, 108, 108f, 116, 143f, 145f, 149, 239
 - ethosuximide, 143f, 145f, 149, **149**
 - gabapentin, 143f, 149, **149-150**
 - lamotrigine, 143f, 149, **149-150**
 - phenobarbital, 23-24, 90f, 94, 95, 97f, 143f, 145f, 148, 148f, 213, 253, 343, 347, 438
 - phenytoin (DILANTIN), 13, 143f, 145f, 146, 146, 146f, **146-147**, 147f, 150, 174, 239, 253, 295, 333, 341, 362, 408f
 - primidone, 143f, 145f, 148, **148**, 148f
 - valproic acid (DEPAKOTE), 143f, 145f, 148, **148-149**, 149f, 150
- Antiestrogens**, **266**
- mechanism of action, 393f
- Antiestrogens, specific agents**, 263f
- clomiphene, 263f, **266**, 266
 - tamoxifen (NOLVADEX), 263f, **266**, 266, 373f, 393, **393-394**, 399f
- Antifungal drugs**, **337-344**
- Antifungal drugs, specific agents**, 337f
- amphotericin B, 284f, 337, 337f, **337-339**, 338f, 339-340, 356
 - clotrimazole, 3-4, 337f, **343**, 343
 - econazole, 337f, **343**, 343
 - fluconazole, 337f, **341-342**, 342, 342f, 429
 - flucytosine, 284f, 337, 337f, 339, 339, 339f, **339-340**, 340
 - griseofulvin, 201f, 337f, 342, **342-343**, 343f
 - itraconazole, 215, 337f, **342**, 342, 342f
 - ketoconazole (NIZORAL), 272, 277,

- 277, 334f, 337f, 340, 340f, **340-341**, 342f
- miconazole (MONISTAT), 337f, **343**, 343
- nystatin, 337f, **343**, 343
- Antigout drugs, specific agents**
- allopurinol, 260f, 356, 382, 402f, 415, 416, **416-417**
- colchicine, 377, 402f, 415, 416, **416**, 416f
- probenecid, 260f, 303, 402f, 408f, 415, 417, **417**
- sulfapyrazone, 402f, 408f, 415, 417, **417**
- Antihelminthic drugs, specific agents**
- ivermectin, 359f, **360**, 360
- mebendazole, 359, **359**, 359f, 361f
- niclosamide, 359f, **362**, 362
- praziquantel, 359f, **360-362**, 362, 362
- pyrantel pamoate, 359, 359f, **359-360**, 361f
- thiabendazole, 359f, **360**, 360, 361f
- Antihistamines, 90f, 96, 96, 107f**
- antiemetic potency, 243f
- as autacoids, 420-425
- in combination therapy, 243
- preanesthetic, 108
- for rhinitis, 221
- specific agents, 217f
- Antihistamines, specific agents**
- astemizole (HISMANAL), 214, 221, 341, 422f
- azatadine, 422f
- brompheniramine, 422f
- carbinoxamine, 422f
- cetirizine, 422f
- chlorpheniramine, 221, 422f
- cimetidine (TAGAMET), 108, 147, 147f, 201f, 235f, 236, **236-238**, 237f, 326, 340, 347, 362, 419f, 440
- clemastine (TAVIST), 422f
- cyclizine, 242, 419f, 422f, 424, 424
- cyproheptadine, 422f
- dexchlorpheniramine, 422f
- dimenhydrinate, 129f, 242, 419f, 422f, 424, 424
- diphenhydramine, 96, 108, 221, 243, 243f, 392, 419f, 422f, 423-424, 424, 438
- doxylamine, 96, 422f
- famotidine (PEPCID), 235f, 236, **236-238**, 419f, 440, 440f
- hydroxyzine, **93**, 93, 97f, 138, 422f
- loratidine (CLARITIN), 221, 422f
- meclizine, 129f, 242, 419f, 422f, 424, 424
- methdilazine, 422f
- nizatidine (AXID), 235f, 236, **236-238**, 419f, 440
- promethazine (PHENERGAN), 127f-129f, 130, 130, 422f
- pyrilamine, 422f
- ranitidine (ZANTAC), 235f, 236, **236-238**, 419f, 438, 440
- terfenadine (SELDANE), 214, 221, 320, 341, 422f
- timeprazine, 422f
- tripelennamine, 422f
- triprolidine, 422f
- Antihyperlipidemic drugs, 207-216**
- Antihyperlipidemic drugs, specific agents, 207f**
- cholestyramine (QUESTRAN), 207f, 212, 212, 212f, **212-213**, 215
- clofibrate, 207f, 211, 211f, **211-212**, 260f, 334f
- colestipol, 207f, 212, 212, 212f, **212-213**
- fluvastatin, 207f, 213, 214, **214-215**
- gemfibrozil (LOPID), 207f, 211, 211, 211f, **211-212**, 215
- lovastatin (MEVACOR), 207f, 214, **214-215**
- niacin, 207f, 210, 210f, **210-211**, 211, 212, 215
- pravastatin (PRAVACHOL), 207f, 213, 214, 214f, **214-215**
- probucol, 207f, 213, 213, 213f, **213-214**
- simvastatin (ZOCOR), 207f, 214, **214-215**
- Antihypertensive drugs, 179-192**
- Antihypertensive drugs, specific agents, 179f-180f**
- amlodipine (NORVASC), **157**, 180f, 188, 188, 188f
- atenolol (TENORMIN), 71f, 75f, 77, **77**, 79f, 176, 179f, 185
- benazepril, 179f
- bumetanide (BUMEX), 151f, 179f, 223f-224f, 227, **227-228**, 292, 316
- captopril (CAPOTEN), 151f, 179f
- clonidine (CATAPRES), 55f, **67**, 67, 69f, 180f, 189, **189-190**, 442
- diazoxide, 180f, **191**, 191, 292
- diltiazem (CARDIZEM CD, DILACOR XR), 163f, **173**, 173, 173f, 175f, 177, **177**, 180f, 187, 187, 187f-188f
- doxazosin (CARDURA), 71f, **73**, 73, 180f
- enalapril (VASOTEC), 151f, 156, 156, 157f, 179f
- felodipine, **157**, 180f, 188, 188, 188f
- fosinopril, 151f
- furosemide (LASIX), 151f, 179f, 223f, 224, 224f, 227, **227-228**, 292, 316, 409, 439-441
- hydrochlorothiazide, 151f, 179f, 183, 183, 223f, 229, **231**, 441
- isradipine (DYNACIRC), 180f, 188, 188, 188f
- labetalol (NORMODYNE), 71f, 74f, 78, **78**, 79f, 179f, 191
- lisinopril (ZESTRIL, PRINIVIL), 151f, 179f
- losartan, 179f, **187**, 187
- α -Methyldopa, 180f, **190**, 190
- metoprolol (LOPRESSOR), 71f, 74f-75f, 77, **77**, 78f-79f, 171, 176, 179f, 185
- minoxidil (ROGAINE), 151f, 180f, 190, **190-191**
- moexipril, 179f
- nadolol (CORGARD), 71f, 74f, 76, **76**, 78f, 179f, 428
- nicardipine, 180f, 188, 188, 188f
- nifedipine (ADALAT, PROCARDIA XL), 173, 173f, 175f, 177, **177**, 187, 187f, 187-188, 188f
- nisoldipine, 180f, 188, 188
- prazosin (MINIPRESS), 71f, **73**, 73, 124, 180f, 189
- propranolol, 7, 71f, 74, 74f, **74-76**, 75f-76f, 78f-79f, 163f-164f, 171, 175f, 176, 179f, 185, 190, 334f, 427f, 428, 436-437
- propranolol (INDERAL), 190
- quinapril (LOTENSIN), 151f, 179f
- ramipril (ACCUPRIL, ALTACE), 179f
- sodium nitroprusside, 151f, 180f, **191**, 191
- spironolactone, 179f, 183, 183, 223f-224f, **232-233**, 233, 274, 277
- terazosin (HYTRIN), 71f, **73**, 73, 180f, 189
- timolol (TIMOPTOL, TIMOPTIC), 71f, 74f, 76, **76**, 78f-79f, 179f
- triamterene (DYAZIDE), 179f, 223f-224f, 233, **233**
- verapamil (ISOPTIN, VERELAN), 160f, 163f-164f, 167, 169, **173**, 173, 173f, 175f, 177, **177**, 180f, 187, 187, 187f-188f, 189, 377
- Antiinflammatory agents, 401-418. See also Nonsteroidal antiinflammatory drugs**
- slow-acting, **413-415**
- specific agents, 401f-402f
- Antimetabolites, for cancer, 378-384**
- specific agents, 373f
- Antimicrobial agents**
- classification, 287, 287f
- combinations, 284, 284f
- for peptic ulcer disease, 235f, 235-236

- resistance to, 284-286
 selection, 279*f*, **279-282**
 therapy with, principles, **279-288**
- Antimigraine drugs, specific agents**
 β-Adrenergic blockers, 58*f*, 58-59, 60*f*, **73-78**, 74*f*-75*f*, 78*f*-79*f*, 163*f*, 176-177, 178*f*, 182*f*, 184*f*, **184-187**, 185, 185*f*, 188*f*, 409, 419*f*, 427*f*, 428, 436, 442
 dihydroergotamine, 419*f*, **428**, 428
 ergotamine, 419*f*, 427*f*, 428, **428**, 437
 methysergide, 419*f*, 427*f*, 428, 428
 sumatriptan (IMITREX), 419*f*, 426, **426-427**, 427*f*, 437
- Antimotility agents, 244
- Antimuscarinic agents, **45-48**, 81*f*
 for Parkinson's disease, 87-88
 for peptic ulcer disease, 236*f*, 239-240
- Antimycobacterial agents, **331-336**
 specific agents, 331*f*
- Antiparkinson's drugs, specific agents, 81*f***
 amantadine, 81*f*, **87**, 87, 363, 363*f*, **363-364**, 364*f*
 antimuscarinic agents, **45-48**, 81*f*, 87-88, 236*f*, 239-240
 bromocriptine, 81*f*, **87**, 87, 87*f*
 carbidopa (SINEMET), 81*f*, 84-86, 85*f*
 deprenyl, 81*f*, **87**, 87, 87*f*
 levodopa, 8, 81*f*, 84-86, 85*f*-86*f*, 147, 240
 selegiline, 81*f*
- Antiprogestin, 263*f*, **267**
- Antiprogestin, specific agent,**
 mifepristone, 263*f*, 267-268, 277
- Antiprotozoal drugs, **345-358**
- Antiprotozoal drugs, specific agents, 345*f***
 dehydroemetine, 345*f*-346*f*, 348, **348**
 diloxanide furoate, 345*f*-346*f*, 347, 348, **348**
 emetine, 345*f*-346*f*, 348, **348**
 mefloquine, 345*f*, 350*f*, 352, **352-353**
 melarsoprol, 345*f*, 353, 353*f*, **353-354**
 metronidazole, 201*f*, 235*f*, 236, 282, 282*f*, 345*f*-346*f*, 347, **347-348**, 357
 nifurtimox, 345*f*, 353*f*, **355**, 355
 paromomycin, 345*f*-346*f*, 348, **348**
 pentamidine, 339, 345*f*, 353*f*, 356, 370
 pentamidine isethionate, 354, **354-355**
 primaquine, 345*f*, 349, **349-350**, 350, 350*f*-351*f*, 432-433
 quinacrine, 345*f*, 357
 quinidine, 147, 160*f*, 163*f*-164*f*, 167, 167*f*, **167-168**, 169, 171, 172*f*, 214, 334*f*, 345*f*
 quinidine sulfate, 168
 quinine, 345*f*, 350*f*, **352**, 352
 sodium stibogluconate, 345*f*, 356, **356-357**
 suramin, 345*f*, 353*f*, **356**, 356
- Antipseudomonal penicillins, 300*f*, **301**
 adverse reactions, 303
- Antipsychotic drugs, **127-132**
 actions, 128*f*
 adverse effects, 130*f*
 antiemetic uses, 129*f*
 dopamine-blocking agents, 128*f*
 and LSD, 105
 summary, 132*f*
- Antipsychotic drugs, specific agents**
 chlorpromazine, 90*f*, 127, 127, 127*f*-128*f*, 129-131, 131*f*-132*f*
 clozapine, 127*f*, 128, 128, 128*f*, 130-131, 131*f*-132*f*
 fluphenazine, 127, 127, 127*f*-128*f*, 130, 131*f*-132*f*
 haloperidol, 84, 105, 127, 127, 127*f*-129*f*, 130-131, 131*f*-132*f*, 242*f*, 242-243
 haloperidol decanoate, 3, 130
 prochlorperazine (COMPazine), 127*f*, 129, 129*f*, 242, 242, 242*f*, 243
 promethazine (PHENERGAN), 127*f*-129*f*, 130, 130, 422*f*
 risperidone, 127*f*, 128, 128, 128*f*, 130-131, 132*f*
 thioridazine, 127*f*-128*f*, 129, 129, 130, 132*f*
 thiothixene, 127, 127, 127*f*-128*f*, 132*f*
- Antipyretic agents, salicylates as, 404, 406
- Antischizophrenic drugs. *See* Antipsychotic drugs
- Antisecretory agent, atropine as, 47
- Antispasmodic agent, atropine as, 47
- Antistaphylococcal penicillins, **300**, 300*f*
- Antithyroid drugs, specific agents**
 iodide, 247*f*, 254
 levothyroxine (LEVOXYL), 247*f*, 253
 methimazole, 247*f*, 253, 253-254, 436
 propylthiouracil, 247*f*, 253, 253-254, 436
 thyroxine, 247*f*, 251, 252*f*, 408*f*
 triiodothyronine, 247*f*, 251, 252*f*, 408*f*
- Antituberculosis drugs, specific agents**
 aminosalicilic acid, 331*f*, **335**, 335
 cycloserine, 331*f*, **335**, 335
 ethambutol, 331, 331*f*, 334, **334-335**, 335*f*, 437
 ethionamide, 331*f*, **335**, 335
 isoniazid, 147, 147*f*-148*f*, 283, 283*f*-284*f*, 331, 331*f*, 332, 332, 332*f*, **332-333**, 333*f*, 334, 335*f*, 437
 pyrazinamide, *f*, 284*f*, 331, 334, **334**, 334, 335, 437
 rifampin, 201*f*, 253, 284*f*, 285, 285*f*, 287*f*, 300, 331, 331*f*, 333, **333-334**, 334, 340-341, 437
- Antiviral drugs, **363-372**
- Antiviral drugs, specific agents, 363*f***
 acyclovir (ZOVIRAX), 363*f*, 365, 365, **365-366**, 366*f*-367*f*
 amantadine, 81*f*, **87**, 87, 363, 363*f*, **363-364**, 364*f*
 didanosine (ddl), 363*f*, 369, 369*f*, **369-370**
 famciclovir, 363*f*, **367**, 367
 foscarnet, 363*f*, **367**, 367
 ganciclovir (DHPG), 363*f*, 366, **366-367**
 interferons, 363*f*, **371**, 371, 371*f*, 373*f*, **397-398**, 399*f*
 ribavirin, 363*f*, 364, **364-365**
 rimantadine, 363, 363*f*, **363-364**
 stavudine (d4T), 363*f*, 369*f*, **370**, 370
 trifluridine, 363*f*, **368**, 368
 vidarabine (ara-A), 363*f*, 367, 367*f*, **367-368**
 zalcitabine (ddC), 363*f*, 369*f*, 370, **370**
 zidovudine (AZT), 339, 363*f*, 367, 368, **368-369**, 369*f*
- Anxiety disorders
 benzodiazepines and, 90
 treatment, 90, 95, 148
- Anxiolytic agents, **89-98**
 specific agents, 89*f*-90*f*
 therapeutic advantages and disadvantages, 97*f*
- APSAC. *See* Anistreplase
- Ara-A. *See* Vidarabine
- Arabinofuranosyl adenine. *See* Vidarabine
- Ara-C. *See* Cytarabine
- Arrhythmias, **163-166**. *See also specific arrhythmia*
 atrial, treatment, 164*f*, 168, 173
 atrioventricular, treatment, 168
 causes, 165
 treatment, 73, 78*f*, 169, 171, 172*f*
 types, 164*f*
- Arterial thrombosis, treatment, 203
- Arthralgia, treatment, 406
- Arthritis
 rheumatoid, treatment, 351, 406, 408, 411, 413-415
 treatment. *See* Antiarthritis drugs, specific agents
- Ascaris lumbricoides* infection, 361*f*-362*f*
 treatment, 359, 361*f*
- L-Asparaginase, 373*f*, 397, **397**, 399*f*
 mechanism of action, 398*f*

- Asparaginase, emetic potential, 241*f*
 Aspergillosis, treatment, 342
 Aspirin, 193*f*, 196, **196**, 196, 401*f*, 403, **403-408**, 439-440
 for diarrhea, 244, 244*f*
 dose, 407*f*
 drug interactions, 140, 201*f*, 211, 213
 half-life, 407*f*
 metabolism, 13, 404*f*
 for migraine, 427*f*, 428
 and prostaglandin synthesis inhibition, 405*f*
 therapeutic advantages and disadvantages, 412*f*
 Astemizole (HISMANAL)
 drug interactions, 214, 341
 for rhinitis, 221
 therapeutic advantages and disadvantages, 422*f*
 Asthma, 431
 and angina, 178*f*
 and hypertension, 182*f*-183*f*
 treatment, 3, 48, 62-63, 67-68, 189, **217-220**, 218*f*, 276
 specific agents, 217*f*
 Atenolol (TENORMIN), 71*f*, **77**, 77, 79*f*, 179*f*
 actions, 75*f*
 for angina, 176
 for hypertension, 185
 ATIVAN. *See* Lorazepam
 Atracurium, 45*f*, 107*f*
 with anesthesia, 109
 onset and duration of action, 52*f*
 therapeutic advantages, 52*f*
 Atrial fibrillation, treatment, 164*f*, 173-174
 Atrial flutter, treatment, 164*f*, 173-174
 Atrioventricular nodal reentry, treatment, 164*f*
 Atropine (DONNATAL), 45, 45*f*, **45-48**, 49*f*
 and acetylcholine, 40
 actions, 41, 41*f*
 administration route, 4
 dose-dependent effects, 47
 drug interactions, 42-43, 64
 and muscarinic receptor, 46*f*
 structure, 220, 220*f*
 ATROVENT. *See* Ipratropium
 Attention deficit syndrome, treatment, 104
 Atypical depression, treatment, 124
 Auranofin, 413-414
 Aurothioglucose, 413-414
 Autacoids, **419-428**
 specific agents, 419*f*
 Autolysins, 299
 Autonomic hyperreflexia, treatment, 72
 Autonomic nervous system, 27*f*, **27-34**, 32*f*
 cholinergic agonists in, **35-44**, 36*f*
 AXID. *See* Nizatidine
 Azacytidine, emetic potential, 241*f*
 Azatadine, therapeutic advantages and disadvantages, 422*f*
 Azathioprine, 380
 drug interactions, 417
 3'-Azido-3'-Deoxythymidine. *See* Zidovudine
 Azithromycin (ZITHROMAX), 311*f*, 317-320
 antimicrobial activity, 318, 319*f*
 Azlocillin, 298*f*, 301, 301
 administration route, 302
 stability to acid, 300*f*
 AZMACORT. *See* Triamcinolone
 AZT. *See* Zidovudine
 Aztreonam, 298*f*, **307**, 307
 structure, 307*f*
 Bacilli
 gram-negative, 283*f*
 gram-positive, 283*f*
Bacillus anthracis infection, treatment, 299*f*
 Bacitracin, 298*f*, **309**, 309
 Baclofen, 50
 Bacterial prostatitis, treatment, 281
 Bactericidal drugs, 282*f*, 283
 Bacteriostatic drugs, 282*f*, 283
Bacteroides fragilis infection, treatment, 304, 305*f*, 321
 BACTRIM. *See* Trimethoprim
 Barbiturates, **94-96**, 107*f*, 115-116
 dependence potential, 100*f*
 drug interactions, 201*f*
 duration of action, 95
 preanesthetic, 108
 specific agents, 90*f*
 therapeutic advantages and disadvantages, 97*f*
 toxicity (poisoning), 96
Barbiturates, specific agents
 amobarbital, 90*f*, 94, 95, 97*f*
 pentobarbital, 90*f*, 94, 95, 97*f*, 108
 phenobarbital, 23-24, 90*f*, 94, 95, 97*f*, 143*f*, 145*f*, 148, 148*f*, 213, 253, 343, 347, 438
 secobarbital, 90*f*, 94, 95, 97*f*
 Beclomethasone (BECONASE, VANCENASE, VANCERIL), 431
 administration route, 276*f*
 for asthma, 219
 drug elimination, 276*f*
 for rhinitis, 221
 Beclomethasone dipropionate, 276, 276
 BECONASE. *See* Beclomethasone
 Benazepril, 179*f*
 Benign prostatic hyperplasia, treatment, 73, 272
 Benzathine penicillin G, administration route, 302
 Benzisoxazoles, 127*f*
 Benzodiazepine receptor antagonists, 94
Benzodiazepine receptor antagonists, specific agents, 90*f*
 flumazenil, 90*f*, **94**, 94
 Benzodiazepines, **89-93**, 107*f*, 116
 antiemetic potency, 243*f*
 antiepileptics effects, 149
 for chemotherapy-induced nausea and vomiting, 242*f*, 243
 in combination therapy, 243
 duration of action, 92*f*
 preanesthetic, 108
 therapeutic advantages and disadvantages, 97*f*
 withdrawal reactions, 93*f*
Benzodiazepines, specific agents, 89*f*
 alprazolam (XANAX), 90, 90, 92*f*-94*f*, 97*f*, 242*f*, 243, 438
 buspirone (BUSPAR), **93**, 93, 94*f*, 97*f*
 chlordiazepoxide, 91, 92*f*, 97*f*
 clonazepam (KLONOPIN), 91, 91, 97*f*, 143*f*, 145*f*, 149
 clorazepate (TRANXENE), 91, 91, 92*f*, 97*f*, 143*f*, 149
 diazepam (VALIUM), 50, 90, 90, 90*f*, 91, 91, 92*f*-93*f*, 97*f*, 103, 108, 108*f*, 116, 143*f*, 145*f*, 149, 239
 estazolam, 92*f*
 flurazepam, 91, 91, 92, 92*f*-93*f*, 97*f*, 137
 hydroxyzine, **93**, 93, 97*f*, 138, 422*f*
 lorazepam (ATIVAN), 92*f*-93*f*, 97*f*, 108*f*, 116, 242*f*, 243, 243*f*
 midazolam, 97*f*, 108*f*, 116
 quazepam, 92*f*-93*f*, 97*f*
 temazepam (RESTORIL), 91, 92, 92*f*-93*f*, 97*f*
 triazolam (HALCION), 91, 92, 92*f*-93*f*, 97*f*
 zolpidem (AMBIEN), **93**, 93, 97*f*
 Benzothiazepines, 187, 187
 Benztropine
 and neuroleptic drugs, 130
 for Parkinson's disease, 88
 Benzylpenicillin. *See* Penicillin G
 Betamethasone, 438-439
 properties, 275*f*
 BETAPEN VK. *See* Penicillin V
 Bethanechol, 35*f*, **40**, 40

- drug interactions, 236
- structure, 39f
- BIAXIN. *See* Clarithromycin
- Biguanides, **261**
- Bile acid binding resins, **212-213**
- Bilirubin, drug interactions, 408f
- Bioavailability, **6-7**
 - determination, 7f
- Bioequivalence, 7
- Biotransformation, of epinephrine, 62
- Biperiden, for Parkinson's disease, 87-88
- Bisacodyl, as laxative, 244, 244f
- Bishydroxycoumarin. *See also* Dicumarol
 - adverse effects, 292
- Bismuth (compounds), 235f
 - to eliminate *Helicobacter pylori*, 236
- Bismuth subsalicylate, 244, 244f
 - cost, 282, 282f
- Bladder carcinoma, treatment, 395
- Blastomyces dermatitidis* infection, treatment, 338
- Blastomycosis, systemic, treatment, 355
- Bleeding, drug treatment, **204**
- Bleomycin, 373f, 386, **386-387**, 387f, 399f
 - adverse effects, 378
 - drug interactions, 395
 - emetic potential, 241f
 - myelosuppressive potential, 378f
- Bleomycin peptide antibiotics, actions, 374f
- Blood
 - anesthetic solubility in, 111, 111f
 - coagulation, **196**, 196f
 - drugs affecting, **193-206**
 - specific agents, 193f
- Blood-brain barrier, 8
 - and antibiotics, 281
- Blood flow, and drug distribution, 8
- Blood pressure
 - acetylcholine and, 39-40
 - factors affecting, 180f
 - mechanisms for controlling, 180-181
 - phenylephrine and, 66
- Borrelia burgdorferi* infection, treatment, 312f
- Brain tumors, treatment, 389
- Bran, 244f, 245
- Breast cancer
 - metastatic, treatment, 392, 395
 - treatment, 277, 379, 382, 386, 389, 393, 395
 - effect on endocrine system, 395f
- Bretylium, 163f, **172**, 172
 - as antiarrhythmic, 164f
- Bromocriptine, 81f, **87**, 87
 - adverse effects, 87f
- Brompheniramine, therapeutic
 - advantages and disadvantages, 422f
- Bronchitis, treatment, 324
- Bronchodilators, 431-432, 432f
 - adrenergic agonists as, 67f
- Bronchospasm, treatment, 62-63, 67
- Brugia malayi*, 361f
- Bulimia nervosa, treatment, 122
- Bulking agents, 244-245
- Bumetanide (BUMEX), 151f, 179f, 223f, 227, **227-228**
 - drug interactions, 292, 316
 - site of action, 224f
- BUMEX. *See* Bumetanide
- Bupivacaine, 108f
 - pharmacokinetic properties, 117f
- Buprenorphine, 133f, **141**, 141
- Burkitt's lymphoma, treatment, 379, 389
- Burns, treatment, 270, 291
- BUSPAR. *See* Buspirone
- Buspirone (BUSPAR), **93**, 93
 - adverse effects, 94f
 - therapeutic advantages and disadvantages, 97f
- Butalbital (FIORINAL), 437
 - for migraine, 428
- Butyrophenones, 127f
 - antiemetic potency, 243f
 - for chemotherapy-induced nausea and vomiting, 242f, 242-243
 - in combination therapy, 243
- Caffeine, 99, 99f, **99-100**
 - dependence potential, 100f
 - drug interactions, 326, 428
 - for migraine, 428
- CALAN SR. *See* Verapamil
- Calcitonin, administration route, 3
- Calcium carbonate, 236f, 240
- Calcium channel blockers, 163f
 - adverse effects, 189f
 - for angina, 177
 - specific agents, 175f
 - treatment with concomitant diseases, 178f
 - classes, 187-188
 - drug interactions, 51
 - for hypertension, 187-189
 - actions, 187f
 - with concomitant diseases, 182f
 - therapeutic applications, 188f
- Calcium channel blockers, specific agents, 180f**
- Calcium gluconate, drug interactions,
- 317
- Calluses, treatment, 406
- Cancer
 - anemia with, treatment, 206
 - bladder, treatment, 395
 - breast
 - metastatic, treatment, 392, 395
 - treatment, 277, 379, 382, 386, 389, 393, 395, 395f
 - chemotherapy. *See also* Anticancer drugs
 - principles, **373-378**
 - choriocarcinoma
 - gestational, treatment, 384
 - treatment, 379, 399f
 - colorectal, treatment, 382, 406
 - gastric, treatment, 382
 - head and neck, 379
 - lung
 - oat cell carcinoma, treatment, 396
 - small-cell, treatment, 392
 - treatment, 386, 396
 - ovarian, treatment, 382, 392, 395
 - pancreatic, treatment, 382
 - prostatic, treatment, 272, 394
 - effect on endocrine system, 395f
 - treatment, 386
- Candida* infection, 314
 - candidemia, treatment, 342
 - drug interactions, 340
 - treatment, 338-339, 343
- Candidiasis. *See* *Candida* infection
- Cannabinoids
 - antiemetic potency, 243f
 - for chemotherapy-induced nausea and vomiting, 242f, 243
 - in combination therapy, 243
- Cannabis, dependence potential, 100f
- Canrenone, 232, 232
- Capillary
 - permeability, 8, 8f
 - structure, 8, 8f
- CAPOTEN. *See* Captopril
- Captopril (CAPOTEN), 151f, 179f
- CARAFATE. *See* Sucralfate
- Carbachol, 35f, 40, **40-41**
 - structure, 39f
- Carbamazepine (TEGRETOL), 143f, **147**, 147
 - drug interactions, 147, 147f-148f, 150, 319-320, 362
 - for seizures, 145f
- Carbamylcholine. *See* Carbachol
- Carbapenems, **306-307**
 - specific agents, 298f

- Carbenicillin, 298*f*, 301, 301
administration route, 302
adverse reactions, 303
stability to acid, 300*f*
therapeutic applications, 301*f*
- Carbidopa (SINEMET), 81*f*
dopamine synthesis with, 85*f*
for Parkinson's disease, 84-86
- Carbinoxamine, therapeutic advantages and disadvantages, 422*f*
- Carbonic anhydrase inhibitors, 223*f*
diuretic effects, **226-227**
and sodium retention, 226, 226*f*
- Carboplatin, 373*f*, 395
in cancer therapy, 395-396
emetic potential, 241*f*
myelosuppressive potential, 378*f*
- Carboprost, 419, **419**, 419*f*-420*f*
- Cardiac glycosides, 151*f*. *See also* Digitalis
- Cardiac muscle, contraction, 153-154, 154*f*
- Cardiac output, acetylcholine and, 39
- CARDIZEM CD. *See* Diltiazem
- CARDURA. *See* Doxazosin
- Carmustine, 373*f*, 389, **389-390**
emetic potential, 241*f*
- Cascara, 244
- Case studies, **429-442**
- Castor oil, 244, 244*f*
- CATAPRES. *See* Clonidine
- Catecholamines, 69*f*
- Catechol, structure, 61*f*
- CECLOR. *See* Cefaclor
- Cefaclor (CECLOR), 298*f*
therapeutic advantages and disadvantages, 305*f*
- Cefadroxil (DURICEF), 298*f*
therapeutic advantages and disadvantages, 305*f*
- Cefamandole, 298*f*, 306, 306
adverse effects, 306
therapeutic advantages and disadvantages, 305*f*
vitamin K with, 204
- Cefazolin, 298*f*, 306, 306
therapeutic advantages and disadvantages, 305*f*
- Cefixime (SUPRAX), 298*f*
therapeutic advantages and disadvantages, 305*f*
- Cefmetazole, 298*f*, 304, 304
therapeutic advantages and disadvantages, 305*f*
- Cefonicid, 298*f*
therapeutic advantages and disadvantages, 305*f*
- Cefoperazone, 298*f*, 306, 306
adverse effects, 306
therapeutic advantages and disadvantages, 305*f*
vitamin K with, 204
- Ceforanide, therapeutic advantages and disadvantages, 305*f*
- Cefotaxime, 298*f*, 304, 304
for meningitis, 306
therapeutic advantages and disadvantages, 305*f*
- Cefotetan, 298*f*, 304, 304
therapeutic advantages and disadvantages, 305*f*
- Cefoxitin, 298*f*, 304, 304, 433
for *bacteroides fragilis* infection, 304
therapeutic advantages and disadvantages, 305*f*
- Ceftazidime, 298*f*, 304, 304, 430-431
therapeutic advantages and disadvantages, 305*f*
- CEFTIN. *See* Cefuroxime axetil
- Ceftizoxime, 298*f*
therapeutic advantages and disadvantages, 305*f*
- Ceftriaxone, 298*f*, 304, 304, 435
for gonorrhea, 299*f*
for meningitis, 306
therapeutic advantages and disadvantages, 305*f*
for urinary tract infections, 328*f*
- Cefuroxime, 298*f*
therapeutic advantages and disadvantages, 305*f*
- Cefuroxime axetil (CEFTIN), therapeutic advantages and disadvantages, 305*f*
- Cell-cycle specificity, in anticancer drugs, 374, 376*f*
- Cell wall synthesis inhibitors, **297-310**
specific agents, 298*f*
- Centrally-acting adrenergic drugs, for hypertension, **189-190**
- Central nervous system (CNS), 27, 27*f*
in autonomic control of viscera, 30, 31*f*
infections, 281
neurotransmission in, 81-82
stimulation by ephedrine, 68
- Central nervous system depressants, dependence potential, 100*f*
- Central nervous system stimulants, **99-106**
dependence potential, 100*f*
- Central nervous system stimulants, specific agents, 99*f***
amphetamines, 55*f*, 60-61, 67, **67-68**, 69*f*, 99*f*-100*f*, **103-104**, 104*f*, 105, 138
caffeine, 99, 99*f*, **99-100**, 100*f*, 326, 428
cocaine, 3, 56, 63, 71*f*, **79**, 79, 99*f*-100*f*, 101, **101-103**, 102*f*-103*f*
methylphenidate (RITALIN HYDROCHLORIDE), 99*f*, 104
nicotine, 45*f*, 49, **49**, 49*f*, 99*f*, 100, 100*f*, **100-101**, 101, 101*f*
nicotine gum, 101*f*
theobromine, 99, 99*f*
theophylline (SLO-BID, THEO-DUR), 99, 99*f*, 100, **220**, 222, 319-320, 326, 395
specific agents, 217*f*
- Cephadrine, 298*f*
- Cephalexin (KEFLEX, KEFTAB), 298*f*
therapeutic advantages and disadvantages, 305*f*
- Cephalosporins, **304-305**
first generation, 304
specific agents, 298*f*
therapeutic advantages and disadvantages, 305*f*
- second generation, 304
specific agents, 298*f*
therapeutic advantages and disadvantages, 305*f*
- third generation, 304
specific agents, 298*f*
therapeutic advantages and disadvantages, 305*f*
- structure, 304*f*
therapeutic advantages and disadvantages, 305*f*
for urinary tract infections, 328*f*
vitamin K with, 204
- Cephalosporins, specific agents, 298*f***
first generation
cefadroxil (DURICEF), 298*f*, 305*f*
cefazolin, 298*f*, 305*f*, 306, 306
cephadrine, 298*f*
cephalexin (KEFLEX, KEFTAB), 298*f*, 305*f*
cephalothin, 298*f*, 305*f*
cephapirin, 298*f*, 305*f*
- second generation
cefaclor (CECLOR), 298*f*, 305*f*
cefamandole, 204, 298*f*, 305*f*, 306, 306
cefmetazole, 298*f*, 304, 304, 305*f*
cefonicid, 298*f*, 305*f*
cefotetan, 298*f*, 304, 304, 305*f*
cefoxitin, 298*f*, 304, 304, 305*f*, 433
cefuroxime, 298*f*, 305*f*
cefuroxime axetil (CEFTIN), 305*f*

- third generation
 - cefixime (SUPRAX), 298*f*, 305*f*
 - cefoperazone, 204, 298*f*, 305*f*, 306, 306
 - cefotaxime, 298*f*, 304, 304, 305*f*, 306
 - ceftazidime, 298*f*, 304, 304, 305*f*, 430-431
 - ceftizoxime, 298*f*, 305*f*
 - ceftriaxone, 298*f*-299*f*, 304, 304, 305*f*, 306, 328*f*, 435
 - moxalactam, 204, 298*f*
- Cephalothin, 298*f*
 - therapeutic advantages and disadvantages, 305*f*
- Cephapirin, 298*f*
 - therapeutic advantages and disadvantages, 305*f*
- Cephadrine, therapeutic advantages and disadvantages, 305*f*
- Cerebral palsy, treatment, 90
- Cerebrospinal fluid, drug penetration, 281
- Cestodes, chemotherapy, 359*f*, **362**
- Cetirizine, therapeutic advantages and disadvantages, 422*f*
- Chagas' disease, 353, 353*f*
- Chemotherapeutic agents, emetic actions/potential, 241*f*, 242
- Chemotherapy
 - for amebiasis, 345*f*, **345-348**
 - cancer. *See also* Anticancer drugs
 - curative, 375*f*
 - nausea and vomiting with, 241*f*, 242
 - treatment, 241-243, 242*f*
 - palliative, 375*f*
 - principles, **373-378**
 - problems with, 377-378
 - for cestodes, 359*f*, **362**
 - for giardiasis, 345*f*, **357**
 - for helminthic infections, 359*f*
 - for leishmaniasis, 345*f*, **356-357**
 - for leprosy, **335-336**
 - for malaria, 345*f*, **349-353**
 - for nematodes, 359*f*, **359-360**
 - for toxoplasmosis, 345*f*, **357**
 - for trematodes, 359*f*, **360-362**
 - for trypanosomiasis, 345*f*, **353-356**
 - for tuberculosis, **332-335**
- Chicken pox, treatment, 412
- Chlamydia infection, 283*f*, 290*f*
 - lymphogranuloma venereum, 290*f*
 - treatment, 290, 312*f*, 317-318, 318*f*, 324, 328*f*
- Chloral hydrate, 90*f*, **96**, 96
- Chloramphenicol, 282*f*, 283, 311*f*, 320, **320-321**
 - classification, 287*f*
 - drug interactions, 147, 147*f*, 201*f*, 260*f*
 - effect on neonates, 282
 - metabolism, 15
 - resistance to, 285*f*
 - safety, 282
- Chlordiazepoxide, 91
 - for alcohol withdrawal, 91
 - duration of action, 92*f*
 - therapeutic advantages and disadvantages, 97*f*
- Chloroform, 107
- Chloroguanide, 350*f*
- Chloroquine, 345*f*, 350*f*, 351, **351-352**, 402*f*
 - adverse effects, 352, 352*f*
 - antiinflammatory effects, 414
 - drug interactions, 350
 - sites of action, 346*f*
- Chloroquine phosphate, 432-433
- Chlorothiazide, 223*f*, **229-231**, 231
 - hyperuricemia with, 224
- Chlorotrianisene, 263, 263, 263*f*
- Chlorpheniramine
 - for rhinitis, 221
 - therapeutic advantages and disadvantages, 422*f*
- Chlorpromazine, 127, 127, 127*f*, 129, 132*f*
 - actions, 128*f*
 - affinities at dopaminergic receptors, 131*f*
 - for hiccups, 130
 - ratio of lethal to effective dose, 90*f*
 - for schizophrenia, 131
- Chlorpropamide, 255*f*, 260, 260-261
 - properties, 261*f*
- Chlorthalidone, 223*f*, 229, **231**, 231
- Cholera, treatment, 312*f*
- Cholesterol, niacin for, 210
- Cholestyramine (QUESTRAN), 207*f*, 212, **212-213**
 - in combination drug therapy, 215
 - mechanism of action, 212, 212*f*
- Choline magnesium salicylate, 406
- Choline, recycling, 37, 37*f*
- Cholinergic agents, adverse effects, 40*f*
- Cholinergic agonists, **35-44**
 - adverse effects, 49*f*
 - antidote for, 47
 - indirect, mechanisms of action, 41, 42*f*
 - reversible, mechanisms of action, 41, 42*f*
 - sites of action, 36*f*
 - structures, 39*f*
- Cholinergic agonists, specific agents,**
 - 35*f*
 - acetylcholine, 21, 32*f*, 33, 35*f*, 36-37, 37*f*, 39, 39*f*, **39-40**, 46*f*, 236
 - bethanechol, 35*f*, 39*f*, 40, **40**, 236
 - carbachol, 35*f*, 39*f*, 40, **40-41**
 - pilocarpine, 35*f*, **41**, 41, 41*f*, 75, 227
- Cholinergic antagonists, **45-54**
 - for asthma, 220
 - sites of action, 46*f*
 - specific agents, 45*f*
 - summary, 49*f*
- Cholinergic, definition, 33
- Cholinergic neurons, **35-37**
- Cholinergic receptors, **38-39**
 - types, 38*f*
- Choline salicylate, 406
- Cholinesterase inhibitors, drug interactions, 51
- Cholinesterase inhibitors, specific agents**
 - echothiophate, 35*f*, **43**, 43
 - edrophonium, 35*f*, **43**, 43, 50-51, 433, 434*f*
 - isofluorophate, 35*f*, **43**, 43
 - neostigmine, 35*f*, **42**, 42, 50-51, 317
 - physostigmine, 35*f*, **42**, 42, 47, 51
 - pyridostigmine, 35*f*, **42**, 42
- Cholinoceptors. *See* Cholinergic receptors
- Choriocarcinoma
 - gestational, treatment, 384
 - treatment, 379, 399*f*
- Chromoblastomycosis, treatment, 339
- Chronic obstructive pulmonary disease and angina, 178*f*
 - and hypertension, 182*f*
 - treatment, 3, 48, 221-222
 - specific agents, 217*f*
- Cigarettes, nicotine concentration, 101*f*
- Cilastatin, 298*f*
 - with imipenem, 306-307
- Cimetidine (TAGAMET), 235*f*, 236, **236-238**, 419*f*, 440
 - drug interactions, 147, 147*f*, 201*f*, 326, 340, 347, 362
 - and gastric acid regulation, 237*f*
 - preanesthetic, 108
- CIPRO. *See* Ciprofloxacin
- Ciprofloxacin (CIPRO), 323, 323, **324**, 325-326
 - for methicillin-resistant staphylococcus aureus, 300
 - therapeutic applications, 325*f*
- Cirrhosis, 226
 - edema with, treatment, 229
- Cisplatin, 373*f*, 395, 399*f*

- actions, 374f
 in cancer therapy, 395-396
 drug interactions, 242-243, 316, 387
 emetic potential, 241f
- Clarithromycin (BIAVIN), 235f, 311f, 317-320, 433
 antimicrobial activity, 317, 319f
 cost, 282, 282f
 to eliminate *Helicobacter pylori*, 236
- CLARITIN. *See* Loratidine
- Class I drugs, 12, 12f
- Class II drugs, 12, 12f
- Clavulanic acid, 298f, 307, **307-308**, 308f
 administration route, 302
 drug interactions, 300-301
 stability to penicillinase, 300f
- Clemastine (TAVIST), therapeutic advantages and disadvantages, 422f
- CLEOCIN-T. *See* Clindamycin
- Clindamycin (CLEOCIN-T), 311f, **321**, 321, 435
 classification, 287f
 resistance to, 285f
- CLINORIL. *See* Sulindac
- Clofazimine, 331f, **336**, 336
- Clofibrate, 207f, 211, **211-212**
 drug interactions, 260f, 334f
 mechanism of action, 211f
- Clomiphene, 263f, **266**, 266
- Clonazepam (KLOPIN), 91, 143f
 antiepileptic effects, 149
 for seizures, 91, 145f
 therapeutic advantages and disadvantages, 97f
- Clonidine (CATAPRES), 55f, **67**, 67, 69f, 180f, 189, **189-190**, 442
- Clorazepate (TRANXENE), 91, 143f
 for alcohol withdrawal, 91
 as antiepileptic, 149
 duration of action, 92f
 therapeutic advantages and disadvantages, 97f
- Clostridia* infection, treatment, 347
- Clostridium difficile* infection
 resistance, 304, 321
 treatment, 308
- Clostridium perfringens* infection, treatment, 299f
- Clot, formation, 193-194
- Clotrimazole, 337f, **343**, 343
 administration route, 3-4
- Cloxacillin, 298f, 300, 300
 stability to penicillinase, 300f
- Clozapine, 127f, 128, 128, 130-131, 132f
- actions, 128f
 affinities at dopaminergic receptors, 131f
- Cluster headache, characteristics, 425f
- Cocaine, 71f, **79**, 79, 99f, 101, **101-103**
 administration route, 3
 dependence potential, 100f
 drug interactions, 63
 effects, 103f
 mechanism of action, 102f
 and norepinephrine removal, 56
- Cocci
 gram-negative, 283f
 gram-positive, 283f
- Coccidioides immitis* infection (coccidioidomycosis), treatment, 338, 342
- Codeine, 133f, **140**, 140
 absorption, 137
 actions, 134f, 140f
 for cough, 137, 222
 efficacy and addiction/abuse liability, 135f
- Codeine sulfate, for migraine, 427f
- Colchicine, 402f, **416**, 416
 adverse effects, 416f
 for hyperuricemia, 415
 resistance to, 377
- Colestipol, 207f, 212, **212-213**
 mechanism of action, 212, 212f
- Colloidal bismuth, 236f, 241
- Colorectal cancer, treatment, 382, 406
- COMPAZINE. *See* Prochlorperazine
- Condom
 failure rate, 268f
 percent use, 268f
- Gongenital-adrenal-hyperplasia (GAH), treatment, 274-275
- Congestive heart failure
 edema with, treatment, 229
 and hypertension, 182f-183f
 kidney function during, 225
 physiological responses, 154-155, 155f
 treatment, 66, **151-162**, 188f, 228, 230
 specific agents, 151f
 ventricular function curves, 159f
- Congestive heart failure drugs, specific agents, 151f**
 amrinone, 151f, 161, 161, 161f
 bumetanide (BUMEX), 151f, 179f, 223f, 224f, 227, **227-228**, 292, 316
 captopril (CAPOTEN), 151f, 179f
 digitoxin, 151f, 158, 158, 160f, 334f
 digoxin (LANOXIN), 151f, 156, 158, 158, 159, 160f, 163f-164f, 169, 174, 177, 188, 213, 320, 352, 395, 410, 439-441
- dobutamine, 55f, **66**, 66, 69f, 151f, 159, 161, 161f
- enalapril (VASOTEC), 151f, 156, 156, 157f, 179f
- fosinopril, 151f
- furosemide (LASIX), 151f, 179f, 223f, 224, 224f, 227, **227-228**, 292, 316, 409, 439-441
- hydralazine, 151f, 157, 180f, 190, **190**, 442
- hydrochlorothiazide, 151f, 179f, 183, 183, 223f, 229, **231**, 441
- isosorbide (ISORDIL), 151f
- isosorbide dinitrate, **157**, 175f, **176**, 176, 177f
- isosorbide mononitrate, 176
- lisinopril (ZESTRIL, PRINIVIL), 151f, 179f
- metolazone, 151f, 223f, **231**, 231
- milrinone, 151f, 161, 161
- minoxidil (ROGAINE), 151f, 180f, 190, **190-191**
- quinapril (LOTENSIN), 151f, 179f
- sodium nitroprusside, 151f, 180f, **191**, 191
- Constipation, treatment, specific agents, 244f
- Contraception, **267-269**
 failure rate, 268f
 implantable, **267-269**
 oral, **267-269**
 percent use, 268f
- CORGARD. *See* Nadolol
- Corns, treatment, 406
- Coronary artery disease, 207
- Coronary artery thrombosis, treatment, 406
- Corticosteroids
 administration route, 276f
 adverse effects, 277f
 antiemetic potency, 243f
 for asthma, 218-220
 specific agents, 217f
 for chemotherapy-induced nausea and vomiting, 242f, 243
 for chronic obstructive pulmonary disease, specific agents, 217f
 in combination therapy, 243
 drug interactions, 160f
 elimination, 276f
 properties, 275f
 for rhinitis, 221
 specific agents, 217f
 secretion, regulation, 272f
- Corticosteroids, specific agents**

- beclomethasone (BECONASE, VANCENASE, VANCERIL), 219, 221, 276f, 431
 beclomethasone dipropionate, 276, 276
 betamethasone, 275f, 438-439
 cortisone, 275f, 276f
 desoxycorticosterone, 276f
 dexamethasone, 235, 242f, 243, 243f, 275f-276f, 276f, 277, 362, 392, 395
 fludrocortisone, 274, 274, 275f
 hydrocortisone, 274, 274, 275f-276f, 438-439
 methylprednisolone, 219, 242f, 243, 275f-276f
 paramethasone, 275f
 prednisolone, 275f, 393
 prednisone (DELTASONE, ORASONE), 219, 275f, 276, 334f, 373f, 393, **393**, 397, 399f, 438-439
 triamcinolone (AZMACORT), 219, 221, 275f, 276, 276, 276f
 Corticotropin (ACTH), 247f, **249**, 249, 249f
 Corticotropin-releasing hormone, 249f
 actions, 248f
 Cortisol, 272, 274
 production, 272, 272f
 suppression of synthesis, 340
 Cortisone
 administration route, 276f
 elimination, 276f
 properties, 275f
Corynebacterium diphtheriae infection, treatment, 299f, 318f
 Cosyntropin, 249, 249
 COTRIM. *See* Co-trimoxazole
 Cotrimoxazole (COTRIM), 289, 289, 289f, 290, **293-295**
 drug interactions, 201f
 for gonorrhea, 299f
 for Kaposi's sarcoma, 429
 therapeutic application, 290
 Cough, treatment, 137, 140, 222
 specific agents, 217f
 COUMADIN. *See* Warfarin
 Coumarin, drug interactions, 215
 Cramps, treatment, 441-442
 Cromolyn (INTAL), 423, 431
 for asthma, 218f, **220**, 220
 specific agents, 217f
 for rhinitis, 221
 specific agents, 217f
 Cryptococcal meningitis, treatment, 284f
Cryptococcus neoformans infection (cryptococcosis), treatment, 338-339, 341-342
 Crystalline zinc suspension, 258-259
 Cushing's syndrome
 diagnosis, 274
 treatment, 277
 Cutaneous larva migrans, treatment, 360
 Cutaneous leishmaniasis, 356
 Cyanide, nitroprusside and, 191f
 Cyanocobalamin (B₁₂), 193f, **205**. *See also* Vitamin B₁₂
 Cyclizine, 419f, 424
 for motion sickness, 242, 424
 therapeutic advantages and disadvantages, 422f
 Cyclophosphamide, 373f, 388, **388-389**, 389f, 399f
 drug interactions, 395
 emetic potential, 241f
 myelosuppressive potential, 378f
 Cycloserine, 331f, **335**, 335
 Cyclosporine, drug interactions, 147, 215, 239, 320, 326, 339, 341, 410
 Cyproheptadine, therapeutic advantages and disadvantages, 422f
 Cyproterone acetate, 272, 272
 Cystinuria, treatment, 414
 Cystitis, treatment, 328f
 Cytarabine, 373f, 383, **383-384**, 399f
 actions, 374f
 myelosuppressive potential, 378f
 Cytochrome P-450, **14**, 14f
 thyroid hormones and, 253
 Cytomegalic retinitis, treatment, 366-367
 Cytomegalovirus infection
 resistance, 366
 treatment, specific agents, 363f
 Cytopenia, treatment, 398
 Cytosine arabinoside. *See* Cytarabine
 Dacarbazine, emetic potential, 241f
 Dactinomycin, 373f, 384, **384-385**, 399f
 actions, 374f
 emetic potential, 241f
 interaction with nucleic acids, 21
 resistance to, 377
 Danazol, 263f, 270, 270, 271
 Dantrolene, 50
 with anesthesia, 113
 for hyperthermia, 53
 Dapsone, 331f, 335, **335-336**
 DARVOCET-N. *See* Propoxyphene
 DARVON. *See* Propoxyphene
 Daunorubicin, 373f, 382, 385, **385-386**
 actions, 374f
 DAYPRO. *See* Oxaprozin
 ddC. *See* Zalcitabine
 ddl. *See* Didanosine
 Deep-vein thrombosis, treatment, 198, 201, 203
 Dehydroemetine, 345f, **348**, 348
 sites of action, 346f
 Dehydroepiandrosterone, production, 272
 DELTASONE. *See* Prednisone
 Demeclocycline, 311f, 314, 314
 DEMULEN. *See* Ethinyl estradiol
 Deoxycorticosterone, properties, 275f
 DEPAKOTE. *See* Valproic acid
 Deprenyl, 81f, **87**, 87
 in dopamine metabolism, 87f
 Depression, treatment, 120, 122-124
 Dermatophytosis, treatment, 4
 Desipramine, 119, 119, 119f
 therapeutic advantages and disadvantages, 125f
 Desmopressin, 247f, **251**, 251
 administration route, 3
 DESOGEN. *See* Ethinyl estradiol
 Desoxycorticosterone
 administration route, 276f
 elimination, 276f
 Dexamethasone, 242f
 administration route, 276f
 antiemetic effects, 235
 for chemotherapy-induced nausea and vomiting, 243
 in combination therapy, 243, 243f
 drug interactions, 277, 362, 392, 395
 elimination, 276f
 properties, 275f
 Dexamethasone suppression test, 274
 Dexchlorpheniramine, therapeutic advantages and disadvantages, 422f
 Dextromethorphan, 140, 222
 for cough, 137, 222
 specific agents, 217f
 DFP. *See* Isoflurophate
 DHPG. *See* Ganciclovir
 DIABETA. *See* Glyburide
 Diabetes insipidus, treatment, 3, 230
 Diabetes mellitus, **255-257**
 and angina, 178f
 insulin-dependent, 255, **256**, 256f
 and hypertension, 182f-183f
 insulin release, 256f
 non-insulin-dependent, 255, 256f, **256-257**

- insulin release, 256f
 treatment, 257f, 261
 treatment, 77, 189
 Diabetic neuropathy, treatment, 122
 Diaphragm (contraceptive)
 failure rate, 268f
 percent use, 268f
 Diarrhea, treatment, 137, 235
 specific agents, 244f
 Diazepam (VALIUM), 50, 90, 108f, 116, 143f
 for alcohol withdrawal, 91
 antiepileptic effects, 149
 for anxiety disorders, 90
 and cocaine, 103
 drug interactions, 239
 duration of action, 92f
 for epilepsy, 91
 preanesthetic, 108
 ratio of lethal to effective dose, 90f
 for seizures, 145f
 therapeutic advantages and disadvantages, 97f
 withdrawal reactions, 93f
 Diazoxide, 180f, 191, 191
 drug interactions, 292
 Dibenzodiazepines, 127f
 Diclofenac (VOLTAREN), 401f, 411, 411
 Diclloxacin, 298f, 300, 300
 stability to penicillinase, 300f
 Dicumarol, 199, 199-201
 drug interactions, 147, 147f, 260f
 Didanosine (ddl), 363f, 369, 369f, 369-370
 Dideoxycytidine. *See* Zalcitabine
 Dideoxyinosine. *See* Didanosine
 Diethylcarbamazine, 361f
 Diethyl ether, 107
 Diethylstilbestrol, 263, 263, 263f, 268
 adverse effects, 266
 in cancer therapy, 394
 Diflunisal (DOLOBID), 401f, 403, 403, 406, 408
 therapeutic advantages and disadvantages, 412f
 Digitalis, 157-161
 distribution, 11
 drug interactions, 160f, 184, 214, 339
 epinephrine and, 63
 mechanism of action, 158f
 ventricular function curves, 159f
 Digitoxin, 151f, 158, 158
 drug interactions, 334f
 properties, 160f
 Digoxin (LANOXIN), 151f, 158, 158, 163f, 439-441
 antiarrhythmic effects, 164f, 174
 for congestive heart failure, 159
 drug interactions, 156, 160f, 169, 188, 213, 320, 352, 395, 410
 properties, 160f
 verapamil and, 177
 Dihydroergotamine, 419f, 428, 428
 Dihydropyridines, 187-188
 5- α -Dihydrotestosterone (DHT), 270
 Dihydroxyphenylalanine, in norepinephrine synthesis, 55
 Diisopropylfluorophosphate. *See* Isofluorophate
 DILACOR. *See* Diltiazem
 DILANTIN. *See* Phenytoin
 Diloxanide furoate, 345f, 348, 348
 drug interactions, 347
 sites of action, 346f
 Diltiazem (CARDIZEM CD, DILACOR XR), 163f, 173, 173, 175f, 177, 177, 180f, 187, 187
 actions, 187f
 for angina, 188f
 drug interactions, 188f
 effects, 173f
 for hypertension, 188f
 for supraventricular tachyarrhythmia, 188f
 Dimenhydrinate, 419f, 424
 antiemetic effects, 129f
 for motion sickness, 242, 424
 therapeutic advantages and disadvantages, 422f
 Dimercaprol, drug interactions, 414
 Dinoprost, 419, 419, 419f-420f
 Dinoprostone, 419, 419, 419f-420f
 Diphenhydramine, 96, 419f, 423, 424, 438
 in combination therapy, 243, 243f
 drug interactions, 392
 for motion sickness, 424
 preanesthetic, 108
 for rhinitis, 221
 therapeutic advantages and disadvantages, 422f
 Diphenhydrinate, therapeutic advantages and disadvantages, 422f
 Diphenoxylate, 244, 244, 244f
 for diarrhea, 235
 Diphenylalkalines, 187
 Diphenylhydantoin. *See* Phenytoin
 Dipyrindamole (PERSANTINE), 193f, 196, 196
 Discoid lupus erythematosus, treatment, 351
 Disopyramide, 163f, 169, 169
 effects, 167f
 Distribution, drug, 1, 1f, 7-9, 7-9
 with elimination, 10f
 volume, 9f, 9-11
 and elimination, 25
 without elimination, 10f
 Disulfiram, 96
 drug interactions, 201f
 Dithromycin, 317, 317
 Diuretics, 157
 and changes in urine composition, 233f
 for hypertension, with concomitant diseases, 182f
 sites of action, 224f
Diuretics, specific agents, 151f, 179f, 223f
 acetazolamide, 41, 223f-224f, 226f, 226-227, 233f, 292
 amiloride, 223f-224f, 233, 233
 bumetanide (BUMEX), 151f, 179f, 223f-224f, 227, 227-228, 292, 316
 chlorothiazide, 223f, 224, 229-231, 231
 chlorthalidone, 223f, 229, 231, 231
 ethacrynic acid, 224f, 227, 227-228, 316
 furosemide (LASIX), 151f, 179f, 223f, 224, 224f, 227, 227-228, 292, 316, 409, 439-441
 hydrochlorothiazide, 151f, 179f, 183, 183, 223f, 229, 231, 441
 indapamide (LOZOL), 223f, 231, 231
 mannitol, 223f, 233, 233
 metolazone, 151f, 223f, 231, 231
 spironolactone, 179f, 183, 183, 223f-224f, 232-233, 233, 274, 277
 torsemide, 223f-224f, 227, 227-228
 triamterene (DYAZIDE), 179f, 223f-224f, 233, 233
 urea, 223f, 233, 233
 Dobutamine, 55f, 66, 66, 69f, 151f
 for congestive heart failure, 159, 161, 161f
 Docusate sodium, 244f, 245
 DOLOBID. *See* Diflunisal
 Domperidone, 242f
 antiemetic effects, 129f
 for chemotherapy-induced nausea and vomiting, 242-243
 DONNATAL. *See* Atropine
 DOPA. *See* Dihydroxyphenylalanine
 L-Dopa. *See* Levodopa
 Dopamine, 55f, 65, 65-66, 69f
 actions, 66f, 248f
 for congestive heart failure, 161f
 and neurotransmission, 56

- treatment, 294*f*, 301*f*, 304, 308, 308*f*, 315*f*, 324, 325*f*, 329
- Esmolol, **77**, 77, 163*f*, **171**, 171
clinical applications, 78*f*
drug elimination, 74*f*
- Estazolam, duration of action, 92*f*
- ESTRACE. *See* Estradiol
- ESTRADERM. *See* Estradiol
- Estradiol (ESTRACE, ESTRADERM), 263, 263, 263*f*, 270
menstrual cycle and, 266, 267*f*
metabolism, 265
transdermal path for, 264
- Estriol, 263, 263, 263*f*
- Estrogen replacement therapy, 264, 265*f*
- Estrogens (PREMARIN), 263, **263-266**, 268, 373*f*, 399*f*
adverse effects, 266, 266*f*
in cancer therapy, 394
failure rate, 268*f*
- Estrogens, specific agents**, 263*f*
chlorotrianisene, 263, 263, 263*f*
diethylstilbestrol, 263, 263, 263*f*, 266, 268, 394
estradiol (ESTRACE, ESTRADERM), 263, 263, 263*f*, 264-266, 267*f*, 270
estriol, 263, 263, 263*f*
estrone, 263, 263, 263*f*
ethinyl estradiol (TRI-LEVLIN, DEMULEN, LO/OVRAL, OVCON, TRI-NORINYL, TRIPHASIL, LOESTRIN-FE, DESOGEN), 263, **263**, 263*f*, 265, 268, 394
mestranol, 263*f*, 265, 268
quiestrol, 263, 263, 263*f*
- Estrone, 263, 263, 263*f*
- Ethacrynic acid, 223*f*, 227, **227-228**
drug interactions, 316
site of action, 224*f*
- Ethambutol, 331, 331*f*, 334, **334-335**, 437
adverse effects, 335*f*
- Ethanol
dependence potential, 100*f*
metabolism, 13
- Ethanol, 96
- Ethanolamines, therapeutic advantages and disadvantages, 422*f*
- Ether, minimal alveolar concentration, 111*f*
- Ethinyl estradiol (TRI-LEVLIN, DEMULEN, LO/OVRAL, OVCON, TRI-NORINYL, TRIPHASIL, LOESTRIN-FE, DESOGEN), 263, **263**, 263*f*, 265, 268
in cancer therapy, 394
pharmacokinetics, 268
- Ethionamide, 331*f*, **335**, 335
- Ethosuximide, 143*f*, **149**, 149
for seizures, 145*f*
- Ethylenediamines, therapeutic advantages and disadvantages, 422*f*
- Etodolac (LODINE), 401*f*, 409, **410**
- Etomidate, 108*f*, 116, 116
- Etoposide, 373*f*, 396, **396**, 399*f*
drug interactions, 386
emetic potential, 241*f*
mechanism of action, 397*f*
myelosuppressive potential, 378*f*
- Ewing's soft tissue sarcoma, 390
- Excitatory postsynaptic potentials (EPSP), 82, 82*f*
- Exophthalmos, treatment, 435*f*, 435-436
- Famciclovir, 363*f*, **367**, 367
- Familial combined (mixed) hyperlipidemia, 209*f*. *See also* Hyperlipoproteinemia, type IIB
- Familial dysbetalipoproteinemia, 209*f*. *See also* Hyperlipoproteinemia, type III
treatment, 211
- Familial hypercholesterolemia, 209*f*. *See also* Hyperlipoproteinemia, type IIA
combination drug therapy, 215, 215*f*
- Familial hyperchylomicronemia, 209*f*. *See also* Hyperlipoproteinemia, type I
- Familial hypertriglyceridemia, 209*f*. *See also* Hyperlipoproteinemia, type IV
- Familial mixed hypertriglyceridemia, 209*f*. *See also* Hyperlipoproteinemia, type IV
- Famotidine (PEPCID), 235*f*, 236, **236-238**, 419*f*, 440, 440*f*
- Fansidar, 352
- Fatigue, treatment, 441-442
- 5-FC. *See* Flucytosine
- Febrile seizures, **144**, 144*f*-145*f*
treatment, 148
- FELDENE. *See* Piroxicam
- Felodipine, 180*f*, 188, 188
for congestive heart failure, **157**, 188*f*
drug interactions, 188*f*
for hypertension, 188*f*
- Fenamates, 401*f*, **410**
therapeutic advantages and disadvantages, 412*f*
- Fenoprofen, 401*f*, 408, **408-409**
drug interactions, 327
therapeutic advantages and disadvantages, 412*f*
- Fentanyl, 108*f*, 117, 133*f*, **139**, 139
action, 134*f*
distribution, 137
efficacy and addiction/abuse liability, 135*f*
onset and duration of action, 139*f*
preanesthetic, 108
therapeutic advantages and disadvantages, 116*f*
- Ferrous sulfate, for anemia, 205
- Fetal distress, drug contraindications, 251
- Fetal presentation, abnormal, drug contraindications, 251
- Fever, treatment, 432
- Fibrinolysis, 194
- Fibrin, role in clotting, 194
- Filariasis, treatment, 361*f*
- Filgrastim
drug interactions, 392
for Kaposi's sarcoma, 429
for neutropenia, 378
- Finasteride, 272, 272
for benign prostatic hypertrophy, 73
- FIORINAL. *See* Butalbital
- Flecainide, 163*f*, **170**, 170
effects, 170*f*
- FLOXIN. *See* Ofloxacin
- Fluconazole, 337*f*, **341-342**, 342
for Kaposi's sarcoma, 429
properties, 342*f*
- Flucytosine, 337*f*, 339, **339-340**
for cryptococcal meningitis, 284*f*
drug interactions, 337, 340
mode of action, 339, 339*f*
- Fludarabine, 373*f*, **384**, 384
- Fludrocortisone, 274, 274
properties, 275*f*
- Flumazenil, 90*f*, **94**, 94
- Flunisolide (NASACORT), 219
for asthma, 219
for rhinitis, 221
- Fluoroquinolones, **323-327**
classification, 287*f*
effect on children, 282
resistance to, 285*f*
- Fluoroquinolones, specific agents**, 323*f*
ciprofloxacin (CIPRO), 300, 323, 323, **324**, 325, 325*f*, 326
enoxacin, **324**, 324, 326-327
lomefloxacin, **324**, 324, 325
norfloxacin (NOROXIN), 323, 323, **324**, 325, 325*f*, 326
ofloxacin (FLOXIN), **324**, 324, 325-326
- 5-Fluorouracil, 373*f*, 382, **382-383**, 399*f*
actions, 374*f*
drug interactions, 242
emetic potential, 241*f*
mechanism of action, 383*f*
myelosuppressive potential, 378*f*
- Fluoxetine (PROZAC), 119*f*, 122, **122-123**
adverse effects, 123*f*

- structure, 61*f*
- Dopaminergic neurons, and Parkinson's disease, 84-85, 85*f*
- Dose-response curve, 21, 21*f*
- Dose-response quantitation, 20-22
- Douche, percent use, 268*f*
- Doxacurium, 45*f*
onset and duration of action, 52*f*
pharmacokinetics, 51
- Doxazosin (CARDURA), 71*f*, 73, 73, 180*f*
- Doxepin, 96, 119, 119, 119*f*
therapeutic advantages and disadvantages, 125*f*
- Doxorubicin, 373*f*, 385, 385*f*, 385-386, 399*f*
actions, 374*f*
adverse effects, 378
drug interactions, 242
emetic potential, 241*f*
for Kaposi's sarcoma, 429
myelosuppressive potential, 378*f*
- Doxycycline (VIBRAMYCIN), 311*f*, 313, 313
for cholera, 312*f*
drug interactions, 147
phototoxicity, 314
for urinary tract infections, 328*f*
- Doxylamine, 96
therapeutic advantages and disadvantages, 422*f*
- Dronabinol, 105, 105, 242*f*, 243, 243
- Droperidol, 117, 130, 130, 242*f*
antiemetic effects, 129*f*
for chemotherapy-induced nausea and vomiting, 242-243
in combination therapy, 243*f*
drug interactions, 139
plus fentanyl, 108*f*
preanesthetic, 108
- Drug binding, to proteins, 8-9, 11-12
- Drug receptors, 17-26
- Drug structure
chemical, 8
and distribution, 8
- d4T. *See* Stavudine
- Duodenal ulcers, treatment, 239-241
- DURICEF. *See* Cefadroxil
- DYAZIDE. *See* Triamterene
- DYNACIRC. *See* Isradipine
- Dysphoria, treatment, 243
- Dysrhythmias. *See* Arrhythmias
- Echothiophate, 35*f*, 43, 43
for glaucoma, 41
- Eclampsia, treatment, 95
- Econazole, 337*f*, 343, 343
- Edema
kidney function during, 226
treatment, 223, 229, 440-441
- Edrophonium, 35*f*, 43, 43, 433, 434*f*
drug interactions, 51
and neuromuscular blockers, 50
- E.E.S. *See* Erythromycin
- Efferent neurons, 28, 28*f*
- ELAVIL. *See* Amitriptyline
- Elimination, drug, 1, 1*f*, 23-25
by kidney, 23, 23*f*
- Emboli, 194. *See also* Pulmonary embolism
treatment, 201
- Emesis, chemotherapy-induced, 241*f*, 242
treatment, 241-243, 242*f*
- Emetine, 345*f*, 348, 348
sites of action, 346*f*
- Emodin, 244
- Emodinmega, 244
- E-MYCIN. *See* Erythromycin
- Enalapril (VASOTEC), 151*f*, 156, 156, 179*f*
success rate, 157*f*
- Enanthate, 271
- Endocarditis, treatment, 315
- Endometriosis, treatment, 270
- Enflurane, 107*f*, 113, 113-114
blood/gas partition coefficient, 111*f*
characteristics, 114*f*
minimal alveolar concentration, 111*f*
therapeutic advantages and disadvantages, 116*f*
uptake curve, 112, 112*f*
- Enoxacin, 324, 324, 326-327
- Enoxaprin, 193*f*, 198, 199
adverse effects, 199
- Entamoeba histolytica infection, 345-346
life cycle, 346
treatment, 347-348
- Enteral administration, 2
- Enteric rods, gram-negative, 283*f*, 290*f*
- Enterobacter infection, treatment, 290, 301*f*, 304, 315*f*, 325*f*, 361*f*
- Enterobius vermicularis infection, 361*f*
treatment, 359
- Enterococcal endocarditis, treatment, 284*f*
- Enterococcus faecalis infection
resistance, 308
treatment, 435
- Enterococcus faecium infection,
resistance, 308
- ENTEX LA. *See* Phenylephrine
- Ephedrine, 55*f*, 68, 68, 69*f*
as mixed-action agonist, 61
non-catecholamine, 60
structure, 60*f*
- Epidermophyton infection
(epidermophytosis), treatment, 343, 406
- Epilepsy
classification, 144*f*, 144-145
drug treatment, 143-150
etiology, 143
primary, 143
secondary, 143
treatment, 90-91, 227
- Epinephrine, 33, 55*f*, 61, 61-63, 69*f*
for acute anaphylaxis, 218
administration route, 3
and adrenergic receptors, 58*f*, 58-59
and amine nitrogen, 61
with anesthesia, 118
antiarrhythmic effects, 164*f*
in autonomic nervous system, 32*f*
and bronchodilation, 67*f*
and carbachol, 40
cardiovascular effects, 63*f*
as direct-acting agonist, 61
effect on blood pressure, 72*f*
for glaucoma, 41
and histamines, 424
reversal, 72
structure, 60*f*-61*f*
- Equilin, 263
- Erectile dysfunction, treatment, 420
- Ergotamine, 419*f*, 428, 428, 437
for migraine, 427*f*
- Erosive esophagitis, treatment, 239
- ERYC. *See* Erythromycin
- ERY-TAB. *See* Erythromycin
- Erythromycin (E.E.S., ERYC, E-MYCIN, ERY-TAB), 311*f*, 317, 317, 317-320, 435
antimicrobial activity, 317, 319*f*
contraindications, 282
drug interactions, 148*f*, 215
for mycoplasma pneumonia, 312*f*
therapeutic applications, 290, 318*f*
for urinary tract infections, 328*f*
- Erythromycin base, drug interactions, 160*f*
- Erythromycin ethylsuccinate, 434
- Erythropoietin, 193*f*, 206, 206
for Kaposi's sarcoma, 429
- Escherichia coli infection, 290*f*, 327
and insulin, 257
resistance, 300

- and p-450 metabolism, 122f
 receptor specificity, 121f
 therapeutic advantages and disadvantages, 125f
- Fluoxymesterone, 263f, 271, 271
- Fluphenazine, 127, 127, 127f, 132f
 actions, 128f
 anticholinergic activity, 130
 schizophrenia relapse after, 131f
- Fluphenazine decanoate, metabolism, 130
- Flurazepam, 91
 duration of action, 92f
 for sleep disorders, 91
 as sleep-inducer, 137
 therapeutic advantages and disadvantages, 97f
 withdrawal reactions, 92, 93f
- Flurbiprofen (ANSAID), 401f, 408, **408-409**
- Flutamide, 373f, 399f
 as antiandrogen, 272, 272
 in cancer therapy, 394, 394-395
- Fluticasone
 administration route, 276f
 elimination, 276f
 for rhinitis, 221
- Fluvastatin, 207f, 214, **214-215**
 drug interactions, 213
- Fluvoxamine, 119f, 123, 123
 therapeutic advantages and disadvantages, 125f
- Folate antagonists, **289-296**
- Folate antagonists, specific agents,**
 289f
- cotrimoxazole (COTRIM), 201f, 289, 289, 289f, 290, **293-295**, 299f, 429
- mafenide, 289f, 290
- mafenide acetate, 291
- pyrimethamine, 289f, 290, 290, 293, 345f, 350f, 352-353, 357, 357
- silver sulfadiazine, 289f, 290-291
- succinylsulfathiazole, 289f, 291, 291
- sulfacetamide, 289f, 290
- sulfadiazine, 290
- sulfamethoxazole, 289, 289, 289f, 290, 293, 293f, 294, 315f. *See also* Co-trimoxazole
- sulfasalazine, 289f, 291, 291
- sulfisoxazole, 289f, 290, 292, 292, 328f
- trimethoprim (BACTRIM), 20, 205, 281, 281f, 285, 285f, 287f, 289, 289, 289f, 290, 292f, 293, 293, **293**, 293f, 294, 315f. *See also* Co-trimoxazole
- Folate reduction inhibitors, 289f
- Folate synthesis inhibitors, 289f
- Folic acid, 193f, **205**
 deficiency, 205f
 with vitamin B₁₂, 205
- Folinic acid, 379
 for megaloblastic anemia, 378
- Follicle-stimulating hormone, 250, **250**
 secretion, 250, 250f
- 5-Formyltetrahydrofolic acid. *See* Folinic acid
- Foscarnet, 363f, **367**, 367
- Fosinopril, 151f
- 5-Fu. *See* 5-Fluorouracil
- Furosemide (LASIX), 151f, 179f, 223f, 227, **227-228**, 439-441
 drug interactions, 292, 316, 409
 hyperuricemia with, 224
 site of action, 224f
- Gabapentin, 143f, 149, **149-150**
- Ganciclovir (DHPG), 363f, 366, **366-367**
- Ganglionic blockers, **48-50**, 49f
- Ganglionic blockers, specific agents**
 mecamylamine, 45f, 49f, **50**, 50
 trimethaphan, 45f, 49, **49**, 49f
- Gastric acid secretion, regulation, 236
- Gastric cancer, treatment, 382
- Gastroesophageal reflux disease, treatment, 237
- Gastrointestinal drugs, **235-246**
- Gastrointestinal tract
 absorption in, 4
 infections, treatment, 325f
- Gemfibrozil (LOPID), 207f, 211, **211-212**
 drug interactions, 215
 mechanism of action, 211, 211f
- General anesthetics, 107f-108f
 inhaled, 107f
 intravenous, 108f
- General anesthetics, specific agents**
 diazepam (VALIUM), 50, 90, 90, 90f, 91, 91, 92f-93f, 97f, 103, 108, 108f, 116, 143f, 145f, 149, 239
 droperidol plus fentanyl, 108f
 enflurane, 107f, 111f, 112, 112f, 113, **113-114**, 114f, 116f
 etomidate, 108f, 116, 116
 fentanyl, 108, 108f, 116f, 117, 133f-135f, 137, 139, **139**, 139f
 halothane, 51, 53, 67, 107f, 111, 111f, 112, 112f, 113, **113**, 114f, 116f
 isoflurane, 107f, 111f, 112, 112f, 114, **114**, 114f, 116f
 ketamine, 108f, 116f, 117, **117**
 lorazepam (ATIVAN), 92f-93f, 97f, 108f, 116, 242f, 243, 243f
 methohexital, 108f, 115
 methoxyflurane, 107f, **114**, 114
- morphine, 90f, 100f, 108f, 117, 133f-135f, **135-138**, 139, 139f, 141, 141f, 142
 nitrous oxide, 107f, 111, 111f, 112, 112f, 113, 114, 114f, **114-115**, 116f, 117
 propofol, 108f, 116f, 117, **117**
 sevoflurane, 107f, **115**, 115
 thiamylal, 108f, 115
 thiopental, 9, 90f, 94, 95, 97f, 108f, 109, 115, 115f, 115-116, 116f, 408f
- Genital infections, treatment, 294f
- Gentamicin, 311f, 315, 315, 435
 adverse effects, 316
 drug interactions, 51
 therapeutic applications, 315f
- Gestational choriocarcinoma, treatment, 384
- GHRH. *See* Growth hormone releasing hormone
- Giardia lamblia* infection, 357
 treatment, 347
- Glaucoma
 concomitant with hypertension, treatment, 185
 treatment, 41-42, 63, 74-76, 78f, 227
- Glipizide (GLOUCOTROL), 255f, 260, 260
 properties, 261f
- Glucocorticoids, **272-273**
 inhaled, for asthma, 218f-219f
 production, 272
 properties, 275f
- α -Glucosidase inhibitor, **261**
- GLUCOTROL. *See* Glipizide
- Glutethimide, drug interactions, 201f
- Glyburide (DIABETA, MICRONASE, GLYNASE PRESTAB), 255f, 260, 260
 properties, 261f
- Glycerine suppositories, 244f, 245
- GLYNASE. *See* Glyburide
- Gold salts, 402f, **413-414**
- Gold sodium thiomalate, 413-414
- Gonadal hormone, 250
- Gonadotropin-releasing hormone (GnRH), 247f, **250**
 actions, 248f
 and testosterone, 270
- Gonadotropins, **250**
- Gonococcal ophthalmia, treatment, 299f
- Gonococcal urethritis, acute, treatment, 294f
- Gonorrhea
 oropharyngeal, treatment, 294f
 treatment, 294f, 299f, 324, 325f
- Goserelin, 247f, 250, 250, 373f, 394, 395f

- in cancer therapy, 394
 drug interactions, 395
- Goserelin acetate, 394
- Gout
 chronic, 416
 treatment, 406, 412, **415-417**
 specific agents, 402*f*
- Gouty arthritis, acute, treatment, 409
- Gouty attacks, acute, treatment, 410, 415-416
- Gram-negative microorganisms
 bacilli, 283*f*
 cocci, 283*f*
 enteric rods, 283*f*, 290*f*
 identification, 279-280, 280*f*
 resistance, 284
- Gram-positive microorganisms
 bacilli, 283*f*
 cocci, 283*f*
 identification, 279-280, 280*f*
- Grand mal seizures. *See* Seizures, tonic-clonic
- Granisetron, 242*f*, 243, 243
- Granulocyte stimulating factor, for Kaposi's sarcoma, 429-430
- Griseofulvin, 337*f*, 342, **342-343**, 343*f*
 drug interactions, 201*f*
- Group IA agents, 167
 effects, 167*f*
- Group IB agents, 167, 169
 effects, 169*f*
- Group IC agents, 167, 170
 effects, 170*f*
- Growth fractions, of tumors, 374
- Growth hormone, **249**
- Growth hormone-inhibiting hormone (GHIH), **250**
- Growth hormone-releasing hormone (GHRH), 247*f*, 249
 actions, 248*f*
- Guanethidine, 71*f*, 78, **78-79**
 and norepinephrine release, 56
- Haemophilus influenzae infection
 resistance, 300
 treatment, 294*f*, 301*f*, 304, 306, 317-318, 324, 325*f*
- Hairy cell leukemia, treatment, 384, 398
- HALCION. *See* Triazolam
- Hallucinogens, **104-105**
 dependence potential, 100*f*
- Halogenated hydrocarbon anesthetics, drug interactions, 51
- Haloperidol, 127, 127, 127*f*, 132*f*, 242*f*
 actions, 128*f*
 affinities at dopaminergic receptors, 131*f*
 anticholinergic activity, 130
 antiemetic effects, 129*f*
 for chemotherapy-induced nausea and vomiting, 242-243
 and LSD, 105
 and parkinsonian symptoms, 84
 for schizophrenia, 131
 schizophrenia relapse after, 131*f*
- Haloperidol decanoate
 administration route, 3
 metabolism, 130
- Halothane, 107*f*, **113**, 113
 blood/gas partition coefficient, 111, 111*f*
 characteristics, 114*f*
 drug interactions, 51, 53
 elimination, 112
 methoxamine and, 67
 minimal alveolar concentration, 111, 111*f*
 therapeutic advantages and disadvantages, 116*f*
 uptake curve, 112, 112*f*
- Hansen's disease. *See* Leprosy
- Headache, treatment, 406, 412, 437-438
- Heartburn, treatment, 237
- Heart rate, and acetylcholine, 39
- Heavy metal poisoning, treatment, 414
- Helicobacter pylori infection, 439
 elimination, 239-240
 and peptic ulcer disease, 235-236, 236*f*
- Helminthic infections
 chemotherapy, 359*f*
 incidence, 360*f*
- Hemicholinium, and acetylcholine, 35
- Heparin, 193*f*, **197-199**, 199
 binding to antithrombin III, 198, 198*f*
 drug interactions, 204, 339, 408*f*
- Hepatic ascites, kidney function with, 226
- Hepatitis A virus, treatment, 365
- Hepatitis, treatment, specific agents, 363*f*
- Heroin, 133*f*, **140**, 140
 action, 134*f*
 dependence potential, 100*f*
 distribution, 137
 naloxone and, 141*f*, 142
 naltrexone and, 142
- Heroin withdrawal, treatment, 139
- Herpes simplex encephalitis, treatment, 367*f*
- Herpes simplex virus type 1, treatment, 367
- Herpes simplex virus type 2, treatment, 367
- Herpes virus infection, treatment, **365-368**
 specific agents, 363*f*
- Hexamethonium, and nicotinic receptors, 39
- H₁-Histamine receptor antagonists
 adverse effects, 424*f*
 sites of action, 423*f*
 specific agents, 419*f*
 therapeutic advantages and disadvantages, 422*f*
- Hiccups, treatment, 130
- High-ceiling diuretics. *See* Loop diuretics
- Hirsutism, treatment, 272
- HISMANAL. *See* Astemizole
- Histamine, 420-425
 actions, 421*f*
 biosynthesis, 421*f*
- Histamine H₁-receptor antagonists, 423-425. *See also* Antihistamines
- Histamine H₂-receptor antagonists, **425**, 440. *See also* Antihistamines
 as gastric acid inhibitors, 236-238
 for peptic ulcer disease, 235*f*
 specific agents, 419*f*
- Histoplasma capsulatum infection (histoplasmosis), treatment, 338, 342
- Histrelin, 247*f*, 250, 250
- Hodgkin's disease, 390
 treatment, 388, 393, 396, 399*f*, 409
- Hookworm infection, treatment, 359, 361*f*
- Hormones, **31**
- Hormones, specific agents**
 androgens, 263*f*, 270, 270, 271, 271
 danazol, 263*f*, 270, 270, 271
 fluoxymesterone, 263*f*, 271, 271
 nandrolone, 263*f*, 271, 271
 stanozolol, 263*f*, 271, 271
 testosterone cypionate, 263*f*, 271, 271
- antiandrogens, 73, 272, 272, 373*f*, 394, 394-395, 399*f*
 cyproterone acetate, 272, 272
 finasteride, 73, 272, 272
 flutamide, 272, 272, 373*f*, 394, 394-395, 399*f*
- antiestrogens, 263*f*, 266, **266**, 266, 373*f*, 393, **393-394**, 399*f*
 clomiphene, 263*f*, **266**, 266
 tamoxifen (NOLVADEX), 263*f*, **266**, 266, 373*f*, 393, **393-394**, 399*f*
- antiprogesterin, 263*f*, 267-268, 277
 mifepristone, 263*f*, 267-268, 277
- corticosteroids, 219, 221, 235, 242*f*, 243, 243*f*, 274, 274, 275*f*, 275*f*, 276, 276, 276*f*, 277, 334*f*, 362, 373*f*, 392-393, **393**, 393, 395, 397, 399*f*, 431, 438-439
- beclomethasone (BECONASE,

- VANCENASE, VANCERIL), 219, 221, 276f, 431
- beclomethasone dipropionate, 276, 276f
- betamethasone, 275f, 438-439
- cortisone, 275f, 276f
- desoxycorticosterone, 276f
- dexamethasone, 235, 242f, 243, 243f, 275f-276f, 276f, 277, 362, 392, 395
- fludrocortisone, 274, 274, 275f
- hydrocortisone, 274, 274, 275f-276f, 438-439
- methylprednisolone, 219, 242f, 243, 275f-276f
- paramethasone, 275f
- prednisolone, 275f, 393
- prednisone (DELTASONE, ORASONE), 219, 275f, 276, 334f, 373f, 393, **393**, 397, 399f, 438-439
- triamcinolone (AZMACORT), 219, 221, 275f, 276, 276, 276f
- corticotropin (ACTH), 247f, **249**, 249, 249f
- desmopressin, 3, 247f, **251**, 251
- estrogens, 263, 263, **263**, 263, 263f, 263f, 264-266, 265, 266, 267f, 268, 270, 394
- chlorotrianisene, 263, 263, 263f
- diethylstilbestrol, 263, 263, 263f, 266, 268, 394
- estradiol (ESTRACE, ESTRADERM), 263, 263, 263f, 264-266, 267f, 270
- estriol, 263, 263, 263f
- estrone, 263, 263, 263f
- ethinyl estradiol (TRI-LEVLIN, DEMULEN, LO/OVRAL, OVCON, TRI-NORINYL, TRIPHASIL, LOESTRIN-FE, DESOGEN), 263, **263**, 263f, 265, 268, 394
- mestranol, 263f, 265, 268
- quinestrol, 263, 263, 263f
- gonadotropin-releasing hormone (GnRH), 247f-248f, **250**, 270
- goserelin, 247f, 250, 250, 373f, 394, 394, 395, 395f
- growth hormone-releasing hormone (GHRH), 247f-248f, 249
- histrelin, 247f, 250, 250
- leuprolide, 247f, 250, 250, 373f, 394, 394, 395, 395f, 399f
- luteinizing hormone-releasing hormone (LHRH), 247f-248f
- nafarelin, 247f, 250, 250
- octreotide, 247f, **250**, 250
- oxytocin, 247f, 250, **251**, 251
- progestins, 3, 263f, 267, 267, 268, 268f-269f
- hydroxyprogesterone, 263f, 267, 267
- levonorgestrel, 3, 268, 269f
- medroxyprogesterone (PROVERA), 263f, 267, 267
- norethindrone, 263f, 267, 267, 268
- norgestrel, 263f, 267, 267, 268, 268f
- somatostatin, 247f-248f, **250**
- somatotropin, 247f, **249**, 249
- vasopressin, 247f, 250, **251**, 251
- 5-HT₃ Serotonin receptor blockers, for chemotherapy-induced nausea and vomiting, 242f, 243
- Human chorionic gonadotropin (hCG), **250**
- Human immunodeficiency virus anemia with, treatment, 206
- treatment, **368-371**
- specific agents, 363f
- Human immunodeficiency virus protease inhibitors, **371**
- Human insulin (HUMULIN N), 257
- Human menopausal gonadotropin (hMG), **250**
- HUMULIN. See Human insulin
- Hydralazine, 151f, 180f, **190**, 190, 442
- for congestive heart failure, 157
- Hydrochlorothiazide, 151f, 179f, 183, 183, 223f, 229, **231**, 441
- Hydrocodone, for cough, 222
- Hydrocortisone, 274, 274, 438-439
- administration route, 276f
- elimination, 276f
- properties, 275f
- Hydromorphone, for cough, 222
- Hydrophilic colloids, 244f, 244-245
- Hydroxychloroquine, as antiinflammatory agent, 414
- Hydroxymethylglutaryl-CoA reductase inhibitors, 214f, **214-215**
- adverse effects, 215f
- Hydroxyprogesterone, 263f
- Hydroxyprogesterone acetate, 267, 267
- Hydroxyurea, 193f
- for sickle cell disease, 193, 206
- Hydroxyzine, **93**, 93
- drug interactions, 138
- therapeutic advantages and disadvantages, 97f, 422f
- Hyoscyamine, 236f
- for peptic ulcer disease, 239
- Hyperaldosteronism
- secondary, 226
- treatment, 232
- treatment, 274, 277
- Hypercalcemia, treatment, 228
- Hypercalciuria, treatment, 230
- Hypercholesterolemia
- type IIA, treatment, 213
- type IIB, treatment, 213
- Hypercholesterolemias, treatment, 210
- Hyperlipidemias, 207, 208f-209f
- and hypertension, 182f-183f
- primary, 207
- secondary, 207
- treatment, 214
- type I, 209f
- type IIA, 209f
- type IIB, 209f
- type III, 209f
- type II, treatment, 215
- type IV, 209f
- type V, 209f
- Hyperlipoproteinemia
- treatment, 210
- type IIA, treatment, 212
- type IIB, treatment, 210, 212
- type III, treatment, 211
- type IV, treatment, 210-211
- type V, treatment, 211
- Hypertension
- and angina, 178f
- concomitant disease with, 183f
- etiology, 179
- treatment, 73, 75-78, 78f, 173, 188f, 223, 230-231, 441-442
- treatment strategies, 181-183
- with concomitant diseases, 182f
- Hypertensive emergency, **191**
- Hyperthyroidism, 252
- and epinephrine, 63
- treatment, 75, 253-254
- Hypertriglyceridemias, treatment, 211
- Hyperuricemia, 415
- treatment, 417
- Hypnotic drugs, **89-98**
- specific agents, 89f-90f
- Hypoalbuminemia, and drug binding, 11
- Hypochromic microcytic anemia, and folate deficiency, 205
- Hypoglycemic drugs
- oral, 255f, **255-262**, **260-261**
- adverse effects, 261f
- drug interactions, 260f
- oral, specific agents**
- acetohexamide, 255f, 260, 260, 261f
- chlorpropamide, 255f, 260, 260-261,

- 261f
 glipizide (GLOUCOTROL), 255f, 260, 260, 261f
 glyburide (DIABETA, MICRONASE, GLYNASE PRESTAB), 255f, 260, 260, 261f
 metformin, 255f, **261**, 261, 261f
 tolazamide, 255f, 260, 260, 261f
 tolbutamide, 255f, 260, 260, 261f, 292, 341
 properties, 261f
- Hypoglycemic drugs, specific agents**
 human insulin (HUMULIN N), 257
 insulin, 2-3, 7, 77, 255f, **255-262**, 257, **257-258**, 258f-259f, 259-260, 260f
 insulin zinc suspension, 255f
 intermediate action insulin preparations, **258-259**
 isophane insulin suspension (ILETIN), 255f, **258-259**
 lente insulin, **259**
 prolonged action insulin preparations, **259**
 rapid action insulin preparations, **258**
 semilente insulin, 255f, 259f
 semilente insulin suspension, **258**
 ultralente insulin, 255f, **259**
 zinc insulin, 255f
- Hypogonadism
 primary, treatment, 264
 treatment, 270
- Hypomania, treatment, 125
- Hypothalamic hormones, 247f, **247-250**
 actions, 248f
- Hypothyroidism, 251
 treatment, 253
- HYTRIN. *See* Terazosin
- Ibuprofen (ADVIL, MOTRIN), 401f, 408, **408-409**, 440
 therapeutic advantages and disadvantages, 412f
- Idarubicin, 373f, 385
- Idoxuridine, **368**, 368
- IFN. *See* Interferon
- Ifosfamide, 373f, 388, **388-389**, 389f
- ILETIN. *See* Insulin; Isophane
- Imipenem, 298f, 306, **306-307**
 structure, 307f
- Imipramine, 119, 119, 119f
 for arrhythmias, 171, 172f
 half-life, 120
 and norepinephrine removal, 56
 precautions, 121
 receptor specificity, 121f
 therapeutic advantages and disadvantages, 125f
- IMITREX. *See* Sumatriptan
- IMODIUM. *See* Loperamide
- Indapamide (LOZOL), 223f, **231**, 231
- INDERAL. *See* Propranolol
- Indinavir, **371**, 371
- Indoleacetic acids, **409-410**
 therapeutic advantages and disadvantages, 412f
- Indomethacin, 401f, **409**, 409
 adverse effects, 409f
 for diarrhea, 244, 244f
 drug interactions, 417
 therapeutic advantages and disadvantages, 412f
- Infertility, treatment, 250
- Inflammation, treatment, 275-276
- Inflammatory bowel disease, treatment, 291
- Influenza A infection, treatment, 363, 364f, 365
- Influenza B infection, treatment, 365
- Inhalation administration, **3**
- Inhibitory postsynaptic potentials (IPSP), 82-83, 83f
- INNOVAR, 117
- Inotropic drugs, **157-161**
 specific agents, 151f
- Insomnia, treatment, 424, 435-436
- Insulin, 255f, **255-262**, 257, **257-258**
 administration route, 2-3
 adverse effects, 258, 258f
 bioavailability, 7
 β -blockers and, 77
 extent and duration of action, 259f
 intermediate-acting preparations, **258-259**
 in pregnancy, 260
 preparations, **258-260**
 prolonged action preparations, **259**
 rapid action preparations, **258**
 standard vs. intensive treatment, 259-260, 260f
- Insulin zinc suspension, 255f
- INTAL. *See* Cromolyn
- Interferons, 363f, **371**, 371, 371f, 373f, **397-398**, 399f
- Intra-arterial injection, **3**
- Intramuscular (IM) administration, **3**
- Intranasal administration, **3**
- Intrathecal administration, **3**
- Intrauterine device (IUD)
 failure rate, 268f
 percent use, 268f
- Intravascular administration, **2-3**
- Intravenous (IV) injection, **2-3**, 3f
 kinetics, **17-19**
 multiple, kinetics, 20, 20f
 single, kinetics, 19, 20f
- Intraventricular administration, **3**
- Invermectin, 361f
 contraindications, 359f
- Iodide, 247f, 254
- Ipratropium (ATROVENT), 45f, **48**, 48, 49f, 220
 for asthma, 217f, 220
 for chronic obstructive pulmonary disease, 217f, 222
 structure, 220f
- Iron, 193f, **205**
 erythropoietin and, 206
- Isocarboxazid, 119f, 123, 123
 therapeutic advantages and disadvantages, 125f
- Isoflurane, 107f, **114**, 114
 blood/gas partition coefficient, 111f
 characteristics, 114f
 minimal alveolar concentration, 111f
 therapeutic advantages and disadvantages, 116f
 uptake curve, 112, 112f
- Isoflurophate, 35f, **43**, 43
 for glaucoma, 41
 and reactivation of acetylcholinesterase, 43, 43f
- Isoniazid, 283, 283f, 331, 331f, 332, **332-333**, 437
 adverse effects, 333f
 distribution, 332, 332f
 drug interactions, 147, 147f-148f, 334, 335f
 for tuberculosis, 284f
- Isophane insulin suspension (ILETIN), 255f, **258-259**
- Isoproterenol, 55f, 64, **64-65**, 69f
 actions, 66f
 and adrenergic receptors, 58, 58f
 and amine nitrogen, 61
 blockage by β -blockers, 75
 and bronchodilation, 67f
 cardiovascular effects, 65f
 as direct-acting agonist, 61
 effect on blood pressure, 72f
 structure, 61f
- ISOPTIN. *See* Verapamil
- ISORDIL. *See* Isosorbide
- Isosorbide (ISORDIL), 151f
- Isosorbide dinitrate, 175f, **176**, 176
 for congestive heart failure, **157**
 onset and duration of action, 177f

- Isosorbide mononitrate, onset of action, 176
- Isradipine (DYNACIRC), 180*f*, 188, 188*f*
for congestive heart failure, 188*f*
drug interactions, 188*f*
for hypertension, 188*f*
- Itraconazole, 337*f*, **342**, 342
drug interactions, 215
properties, 342*f*
- Ivermectin, 359*f*, **360**, 360
- Kaolin, 244, 244*f*
- Kaposi's sarcoma, treatment, specific agents, 363*f*
- K-DUR. *See* Potassium
- KEFLEX. *See* Cephalexin
- KEFTAB. *See* Cephalexin
- Ketamine, 108*f*, **117**, 117
therapeutic advantages and disadvantages, 116*f*
- Ketoconazole (NIZORAL), 337*f*, 340, **340-341**
as adrenocorticoid inhibitor, 277, 277
as antiandrogen, 272
drug interactions, 334*f*
mode of action, 340*f*
properties, 342*f*
- Ketoprofen (ORUDIS), 401*f*, 408, **408-409**
drug interactions, 417
therapeutic advantages and disadvantages, 412*f*
- Ketorolac (TORADOL), **411**, 411
- Kidney
collecting ducts, 225, 225*f*
collecting tubules, 225, 225*f*
distal convoluted tubule, 225
drug elimination by, 23, 23*f*
function during disease, 225-226
loop of Henle, 223-224
proximal convoluted tubule, 223-224
regulation of fluid and electrolytes by, 223-225
- Klebsiella infection, resistance, 301
- Klebsiella pneumonia infection, 327
treatment, 304, 315*f*, 325*f*, 433
- KLONOPIN. *See* Clonazepam
- KLOR-CON. *See* Potassium
- Labetalol (NORMODYNE), 71*f*, **78**, 78, 79*f*, 179*f*
drug elimination, 74*f*
for hypertensive emergency, 191
- Labor, premature, terbutaline in, 67
- β -Lactam antibiotics
classification, 287*f*
resistance to, 285*f*
specific agents, 298*f*
structure, 297*f*
- β -Lactamase, drug interactions, 300
- β -Lactamase inhibitors, **307-308**
- β -Lactamase inhibitors, specific agents, 298*f***
clavulanic acid, 298*f*, 300, 300*f*, 301-302, 307, **307-308**, 308*f*
sulbactam, 298*f*, 300, 300*f*, 302, 307, 307
tazobactam, 298*f*, 300*f*, 301-302, 307, 307
- Lactulose, 244*f*, 245
- Lamivudine, **370-371**, 371
- Lamotrigine, 143*f*, 149, **149-150**
- Lanoprazole, 235*f*, 239, 239
- LANOXIN. *See* Digoxin
- LASIX. *See* Furosemide
- Lassa fever, treatment, 365
- Laxatives, **244-245**
specific agents, 244*f*
- Legionella infection, treatment, 294*f*, 317, 324, 325*f*, 326
- Legionellosis. *See* Legionnaires' disease
- Legionnaires' disease, treatment, 318*f*
- Leishmaniasis
chemotherapy, 345*f*, **356-357**
treatment, 355
- Lente insulin, **259**
extent and duration of action, 259*f*
- Leprosy, treatment, 331*f*, **335-336**
- Leptotrichia buccalis infection, treatment, 299*f*
- Leucovorin, 379, 379*f*, 380. *See also* Folinic acid
for anemia, 353
drug interactions, 382, 415
myelosuppressive potential, 378*f*
- Leukemia
acute lymphoblastic, treatment, 381, 390
acute lymphocytic, treatment, 3, 376-377, 379, 386, 393, 397, 399*f*
acute myelocytic, treatment, 386
acute non-lymphocytic (myelogenous), treatment, 382-383
chronic lymphocytic, treatment, 384
chronic myelogenous, for sickle cell disease, 206
treatment, specific agents, 363*f*
- Leuprolide, 247*f*, 250, 250, 373*f*, 394, 395*f*, 399*f*
in cancer therapy, 394
drug interactions, 395
- Levamisole, drug interactions, 382
- Levarterenol, 64, 64
- Levodopa, 81*f*
and blood-brain barrier, 8
distribution, 8
dopamine synthesis with, 85*f*
drug interactions, 86*f*, 147, 240
for Parkinson's disease, 84-86
- Levonorgestrel, 268, 269*f*
administration route, 3
- Levothyroxine (LEVOXYL), 247*f*, 253
- LEVOXYL. *See* Levothyroxine
- Lidocaine, 108*f*, 163*f*, 169, **169**
as antiarrhythmic, 164*f*
for arrhythmias, 174
effects, 169*f*
with epinephrine, 3
metabolism, 7
pharmacokinetic properties, 117*f*
- Lisinopril (ZESTRIL, PRINIVIL), 151*f*, 179*f*
- Listeria monocytogenes infection
resistance, 304
treatment, 299*f*, 300
- Listeriosis, treatment, 299*f*
- Lithium, drug interactions, 410
- Lithium salts, **125**
- Local anesthesia, 108*f*, **117-118**
cocaine as, 102
epinephrine in, 63
- Local anesthetics, specific agents**
bupivacaine, 108*f*, 117*f*
lidocaine, 3, 7, 108*f*, 117*f*, 163*f*-164*f*, 169, **169**, 169*f*, 174
procaine, 108*f*, 117*f*
procaine penicillin G, 302
tetracaine, 108*f*, 117*f*
- LODINE. *See* Etodolac
- LOESTRIN-FE. *See* Ethinyl estradiol
- Log kill, 374
- Lomefloxacin, **324**, 324, 325
- Lomustine, 373*f*, 389, **389-390**
- Loop diuretics, 223*f*, **227-228**
adverse effects, 228*f*
and changes in urine composition, 227*f*, 233*f*
drug interactions, 160, 160*f*
- LO/OVRAL. *See* Ethinyl estradiol
- Loperamide (IMODIUM), 244, 244, 244*f*
- LOPID. *See* Gemfibrozil
- LOPRESSOR. *See* Metoprolol
- Loratidine (CLARITIN)
for rhinitis, 221
therapeutic advantages and disadvantages, 422*f*
- Lorazepam (ATIVAN), 108*f*, 116, 242*f*
for chemotherapy-induced nausea

- and vomiting, 243
 in combination therapy, 243f
 duration of action, 92f
 therapeutic advantages and disadvantages, 97f
 withdrawal reactions, 93f
- Losartan, 179f, **187**, 187
- LOTENSIN. *See* Quinapril
- Lovastatin (MEVACOR), 207f, 214, **214-215**
- LOZOL. *See* Indapamide
- Lung cancer
 oat cell carcinoma, treatment, 396
 small-cell, treatment, 392
 treatment, 386, 396
- Luteinizing hormone, 250
 secretion, 250, 250f
- Luteinizing hormone-releasing hormone (LHRH), 247f
 actions, 248f
- Lyme disease, treatment, 312f
- Lymphogranuloma venereum, treatment, 312f
- Lymphomas. *See also* Hodgkin's disease
 non-Hodgkin's, 390
 treatment, 393
 squamous cell, treatment, 387
 treatment, 386, 393
- Lysergic acid diethylamide (LSD), 99f, **105**
 dependence potential, 100f
- Maalox TC, drug interactions, 370
- MACRO-BID. *See* Nitrofurantoin
- MACRODANTIN. *See* Nitrofurantoin
- Macrolides, **317-329**
 classification, 287f
 resistance to, 285f
- Macrolides, specific agents**, 311f
 azithromycin (ZITHROMAX), 311f, 317-320, 319f
 clarithromycin (BIAXIN), 235f, 236, 282, 282f, 311f, 317-320, 319f, 433
 erythromycin (E.E.S., ERYC, E-MYCIN, ERY-TAB), 148f, 215, 282, 290, 311f, 312f, 317, 317, 317-320, 318f, 319, 319f, 328f, 435
- Mafenide, 289f
 therapeutic application, 290
- Mafenide acetate, for burns, 291
- Magnesium aluminum silicate, 244
- Magnesium hydroxide, 236f, 240, 244f, 245, 439-441
- Magnesium sulfate, 244f, 245
- Major tranquilizers. *See* Neuroleptic drugs
- Malaria, treatment, 345f, **349-353**, 432
- Mania, treatment, 119f, 125
- Manic-depression, treatment, 125, 147
- Mannitol, 223f, 233, 233
- Maprotiline, 119, 119, 119f
 therapeutic advantages and disadvantages, 125f
- Marijuana. *See* Tetrahydrocannabinol
- Mebendazole, 359, **359**, 359f, 361f
 contraindications, 359f
- Mecamylamine, 45f, 49f, **50**, 50
- Mechlorethamine, 373f, 387, **387-388**, 388f, 399f
 emetic potential, 241f
- Meclizine, 419f, 424
 antiemetic effects, 129f
 for motion sickness, 242, 424
 therapeutic advantages and disadvantages, 422f
- Meclofenamate, **410**, 410
 for migraine, 427f
- Meclofenamic acid, therapeutic advantages and disadvantages, 412f
- Medroxyprogesterone (PROVERA), 263f
- Medroxyprogesterone acetate, 267, 267
- Mefenamic acid, **410**, 410
 therapeutic advantages and disadvantages, 412f
- Mefloquine, 345f, 350f, 352, **352-353**
- Melarsoprol, 345f, 353, 353f, **353-354**
- Meningitis
 cryptococcal, treatment, 284f
 treatment, 281, 306, 333, 339
- Menotropin, 250
- Menstrual cycle
 irregular, treatment, 435-436
 progesterone in, 266, 267f
- Mepenzolate, 236f
- Meperidine, 133f, 138, **138-139**, 244
 drug interactions, 338
 efficacy and addiction/abuse liability, 135f
 for migraine, 427f
 onset and duration of action, 139f
- 6-Mercaptopurine, 373f, 380, **380-381**, 399f
 actions, 374f, 381f
 drug interactions, 417
- Mersalyl oxide, 353
- Mestranol, 263f, 265, 268
 pharmacokinetics, 265
- Metabolism, drug, 1, 1f, 12-15, 14f
 effect of drug dose on, 13f
 elimination in, 24, 25f
 hepatic, 7
- Metamucil, 441-442
- Metaproterenol, 55f, **67**, 67, 69f
 and bronchodilation, 67f
- Metaraminol, 55f, **69**, 69
 as mixed-action agonist, 61
- Metformin, 255f, **261**, 261
 properties, 261f
- Methadone, **139**, 139
 drug interactions, 147
 efficacy and addiction/abuse liability, 135f
- Methdilazine, therapeutic advantages and disadvantages, 422f
- Methenamine, 327, 327f, **327-328**
 drug interactions, 292
- Methicillin, 298f, 300, 300
 administration route, 302
 resistance to, 285
 stability to penicillinase, 300f
- Methimazole, 247f, 253, 253-254, 436
- Methohexital, 108f, 115
- Methotrexate, 373f, 378, **378-380**, 399f, 402f, 415
 for abortion, 419
 actions, 374f
 adverse effects, 292, 378
 as antiinflammatory, 415
 drug interactions, 295, 384, 410
 emetic potential, 241f
 and folate deficiency, 205
 as folate reductase inhibitor, 293
 mechanism of action, 379f
 myelosuppressive potential, 378f
- Methoxamine, 55f, 66, **66-67**, 69f
- Methoxyflurane, 107f, **114**, 114
- Methylcellulose, 244, 244f, 245
- α -Methyldopa, 180f, **190**, 190
- Methylphenidate (RITALIN HYDROCHLORIDE), 99f, 104
 for attention deficit syndromes, 104
- Methylprednisolone, 242f
 administration route, 276f
 for asthma, 219
 for chemotherapy-induced nausea and vomiting, 243
 elimination, 276f
 properties, 275f
- Methylsalicylate, 401f, 406, 408
- Methylxanthines, **99-104**
- Methysergide, 419f, 428
 for migraine, 427f, 428
- Metoclopramide (REGLAN), 242, 242, 242f
 antiemetic effects, 129f
 for chemotherapy-induced nausea and vomiting, 242-243

- in combination therapy, 243, 243f
- Metocurine, 45f
onset and duration of action, 52f
pharmacokinetics, 51
- Metolazone, 151f, 223f, **231**, 231
- Metoprolol (LOPRESSOR), 71f, **77**, 77, 79f, 179f
actions, 75f
for angina, 176
antiarrhythmic effects, 171
clinical applications, 78f
drug elimination, 74f
for hypertension, 185
- Metoprolol and pindolol, 163f
- Metronidazole, 235f, 345f, 347, **347-348**
cost, 282, 282f
drug interactions, 201f
to eliminate *Helicobacter pylori*, 236
for giardiasis, 357
sites of action, 346f
- Metyrapone, **277**, 277
- MEVACOR. *See* Lovastatin
- Mexiletine, 163f, **170**, 170
for arrhythmias, 171, 172f
drug interactions, 147
effects, 169f
- Mezlocillin, 298f, 301, 301
administration route, 302
stability to acid, 300f
- Miconazole (MONISTAT), 337f, **343**, 343
- MICRO-K. *See* Potassium
- Micromonospora*, aminoglycosides from, 314
- MICRONASE. *See* Glyburide
- Microsporum* infection, treatment, 343
- Microtubule inhibitors, **390-392**
for cancer, specific agents, 373f
mechanism of action, 391f
- Midazolam, 108f, 116
therapeutic advantages and disadvantages, 97f
- Mifepristone, 263f, 267-268
as adrenocorticoid inhibitor, 277
- Migraine headache
characteristics, 425f
concomitant with hypertension, treatment, 185
treatment, 75, 78f, 187, **425-428**, 427f
specific agents, 419f
- Milrinone, 151f, 161, 161
- Mineralocorticoids, **273-274**
production, 272
properties, 275f
- Mineral oil, 244f, 245
- Minimal alveolar concentrations (MAC), for anesthetic gases, 111, 111f
- MINIPRESS. *See* Prazosin
- MINOCIN. *See* Minocycline
- Minocycline (MINOCIN), 311f, 313, 313, 314
- Minoxidil (ROGAINE), 151f, 180f, 190, **190-191**
- Misoprostol, 235f, 238, 238-239, 267, 267, 419f, 420, 420, 420f
for abortion, 419
drug interactions, 380, 407
and gastric acid regulation, 237f
- Mithramycin. *See* Plicamycin
- Mitomycin, emetic potential, 241f
- Mivacurium, 45f
onset and duration of action, 52f
pharmacokinetics, 51
therapeutic advantages, 52f
- Moexipril, 179f
- MONISTAT IV. *See* Miconazole
- Monoamine oxidase, 123-125
- Monoamine oxidase inhibitors, 119f, **123-125**
drug interactions, 86, 86f, 138, 260f, 425
mechanism of action, 124f
therapeutic advantages and disadvantages, 125f
- Monobactams, **307**
specific agents, 298f
- MOPP regimen, 388
- Moraxella catarrhalis* infection, treatment, 318, 324
- Morganella* infection, treatment, 315f
- Morning-after pill, 268
- Morphine, 108f, 117, 133f, **135-138**
action, 134f
dependence potential, 100f
drug interactions, 141
efficacy and addiction/abuse liability, 135f
naloxone and, 141f, 142
onset and duration of action, 139f
ratio of lethal to effective dose, 90f
withdrawal, treatment, 139
- Motion sickness, treatment, 48, 48f, 130, 242, 424
- MOTRIN. *See* Ibuprofen
- Mountain sickness, treatment, 227
- Moxalactam, 298f
vitamin K with, 204
- 6-MP. *See* 6-Mercaptopurine
- MTX. *See* Methotrexate
- Mucocutaneous leishmaniasis, 356, 356f
- Mucosal protective agents, for peptic ulcer disease, 236f, 241
- Multidrug resistance gene, 377, 377f
- Multiple sclerosis, treatment, 90
- Muscarinic blockers, 49f
- Muscarinic receptors, 38f, **38-39**
- Muscle contraction, physiology, 152f, **153-155**
- Muscle relaxants. *See* Neuromuscular blockers
- Muscular disorders, treatment, 90
- Myalgia, treatment, 406
- Myasthenia gravis, treatment, 68, 433, 434f
- Mycobacterium avium intracellulare* infection, treatment, 318, 333, 336
- Mycobacterium* infection, 436-437
- Mycobacterium kansasii* infection, treatment, 332, 334
- Mycobacterium leprae* infection, 335
treatment, 333
- Mycobacterium tuberculosis* infection, 331.
See also Tuberculosis
resistance, 285
treatment, 332-334
- Mycoplasma, 283f
pneumonia, treatment, 312f, 318f
- Mycoplasma pneumoniae* infection, treatment, 312f
- Mycoses
subcutaneous, treatment, **337-342**
specific agents, 337f
superficial, treatment, **342-343**
specific agents, 337f
systemic, treatment, **337-342**
specific agents, 337f
- Myocardial infarction
acute, treatment, 171, 201, 203
and angina, 178f
and hypertension, 182f-183f
treatment, 185
treatment, 74-76, 186, 196, 198, 202
- Nabilone, 242f, 243
- Nabumetone (RELAFEN), 401f, **411**, 411
- Nadolol (CORGARD), 71f, **76**, 76, 179f
clinical applications, 78f
drug elimination, 74f
for migraine, 428
- Nafarelin, 247f, 250, 250
- Nafcillin, 298f, 300, 300
elimination, 303
stability to penicillinase, 300f
- Nalidixic acid, 323, 323, **327**
- Naloxone, 133f, 141, **141-142**

- action, 134f
and anesthesia, 117
competition with opioid agonists, 141f
drug interactions, 140
- Naltrexone, 133f, **142**, 142
action, 134f
- Nandrolone, 263f, 271, 271
- NAPROSYN. *See* Naproxen
- Naproxen (ANAPROX, NAPROSYN), 401f, 408, **408-409**
drug interactions, 408f, 417
for migraine, 427f, 428
therapeutic advantages and disadvantages, 412f
- Narcolepsy, treatment, 104
- Narcotic analgesics, drug interactions, 138, 138f
- Narcotics, dependence potential, 100f
- NASACORT. *See* Flunisolide
- Nasal decongestant
ephedrine as, 68
phenylephrine as, 66
- Nausea. *See also* Emesis
treatment, 129-130, 424
- Navelbine, 373f
- Necator americanus* infection, 361f
treatment, 359
- Nedocromil, **220**, 220, 431
for asthma, 217f
- Nefazodone, 119f, 123, 123
therapeutic advantages and disadvantages, 125f
- Neisseria gonorrhoeae* infection,
treatment, 294f, 299f, 305f, 325f
- Neisseria* infection, treatment, 304
- Neisseria meningitidis* infection, treatment,
294f, 299f
- Nematode infections
characteristics, 361f
treatment, 359f, **359-360**, 361f
- Neomycin, 311f, 316, 316
adverse effects, 317
- Neostigmine, 35f, **42**, 42
drug interactions, 51, 317
and neuromuscular blockers, 50
- Nephrotic syndrome
kidney function during, 226
treatment, 230, 389
- Nervous system, organization, 27f, **27-31**
- Netilmicin, 311f, 316, 316
adverse effects, 316
- Neuroleptanesthesia, **117**
- Neuroleptic drugs, **127-132**
actions, 128f
adverse effects, 130f
antiemetic uses, 129f
dopamine-blocking agents, 128f
and LSD, 105
summary, 132f
- Neuroleptic drugs, specific agents,**
127f
- chlorpromazine, 90f, 127, 127, 127f-128f, 129-131, 131f-132f
- clozapine, 127f, 128, 128, 128f, 130-131, 131f-132f
- fluphenazine, 127, 127, 127f-128f, 130, 131f-132f
- haloperidol, 84, 105, 127, 127, 127f-129f, 130-131, 131f-132f, 242f, 242-243
- haloperidol decanoate, 3, 130
- prochlorperazine (COMPAZINE), 127f, 129, 129f, 242, 242, 242f, 243
- promethazine (PHENERGAN), 127f-129f, 130, 130, 422f
- risperidone, 127f, 128, 128, 128f, 130-131, 132f
- thioridazine, 127f-128f, 129, 129, 130, 132f
- thiothixene, 127, 127, 127f-128f, 132f
- Neuromuscular blockers, 50-53, 107f**
depolarizing, 53, 53f
duration of action, 52f
mechanism of action, 50f
nondepolarizing (competitive) agents, 50-51
onset of action, 52f
- Neuromuscular blockers, specific agents**
atracurium, 45f, 52f, 107f, 109
doxacurium, 45f, 51, 52f
metocurium, 45f, 51, 52f
mivacurium, 45f, 51, 52f
pancuronium, 45f, 51, 52f
pipecuronium, 45f, 52f
rocuronium, 45f, 51, 52f
succinylcholine, 45f, 52f, 53, 53, **53**, 53f, 107f, 109
tubocurarine, 39, 42, 45f, 50, 50, 50f, 51, 52f
vecuronium, 45f, 51, 52f, 107f, 109
- Neurotransmission
at adrenergic neurons, 55
in central nervous system, 81-82
at cholinergic neurons, **35-37**
- Neurotransmitters, **31-33**
cellular effects, 33f
summary, 32f, 32-33
types, 32
- Neutral protamine Hagedorn. *See* Isophane insulin suspension
- Niacin, 207f, **210-211**, 211
cholesterol levels during, 210f
in combination drug therapy, 215
drug interactions, 212, 215
mechanism of action, 210, 210f
- Nicardipine, 180f, 188, 188
for angina, 188f
drug interactions, 188f
for hypertension, 188f
- Niclosamide, 359f, **362**, 362
- NICORETTE. *See* Nicotine gum
- Nicotine, 45f, 49, **49**, 49f, 99f, 100, **100-101**
actions, 100f
blood concentration, 101f
dependence potential, 100f
withdrawal from, 101
- Nicotine gum, nicotine concentration, 101f
- Nicotinic acid. *See* Niacin
- Nicotinic receptors, 38f, 39
- Nifedipine (ADALAT, PROCARDIA XL), 173, 175f, **177**, 177, 187, 187-188
actions, 187f
for angina, 188f
drug interactions, 188f
effects, 173f
for hypertension, 188f
- Nifurtimox, 345f, 353f, **355**, 355
- Nisoldipine, 180f, 188, 188
- Nitrates
for angina, treatment with concomitant diseases, 178f
effects on smooth muscle, 176, 176f
- Nitrites, effects on smooth muscle, 176, 176f
- NITRO-DUR. *See* Nitroglycerin
- Nitrofurantoin (MACRODANTIN, MACRO-BID), **329**, 329
- Nitroglycerin (NITROSTAT), 175f, **175-176**, 176, 442
administration route, 2, 4
onset and duration of action, 177f
- Nitroprusside, **191**, 191
and cyanide, 191f
- Nitrosoureas, 399f
actions, 374f
in cancer therapy, 389-390
myelosuppressive potential, 378f
- NITROSTAT. *See* Nitroglycerin
- Nitrous oxide, 107f, 114, **114-115**, 117
blood/gas partition coefficient, 111, 111f
characteristics, 114f
elimination, 112
with halothane, 113
minimal alveolar concentration, 111,

- 111f
 therapeutic advantages and disadvantages, 116f
 uptake curve, 112, 112f
- Nizatidine (AXID), 235f, 236, **236-238**, 419f, 440
- NIZORAL. *See* Ketoconazole
- Nocardia asteroides*, 290f
- Nocardia* infection, treatment, 290, 290f
- NOLVADEX. *See* Tamoxifen
- Nonbarbiturate sedatives, **96**
- Nonbarbiturate sedatives, specific agents**, 90f
- antihistamines, 90f, 96, **96**, 107f, 108, 221, 243, 243f, 419f, 420-425
 specific agents, 217f
- chloral hydrate, 90f, **96**, 96
- polycyclic antidepressants, 119f, **119-121**, 120f, 125f
- tricyclic antidepressants, 42, 119f, **119-121**, 120f-122f, 125f, 138
- Non-catecholamines, 60, 69f
- Non-Hodgkin's lymphomas, 390
 treatment, 393
- Non-narcotic analgesics, **411-413**
- Non-narcotic analgesics, specific agents**, 401f
- acetaminophen (TYLENOL), 140, 401f, 405f, 407, 412, **412-413**, 413f, 428
- phenacetin, 401f, 412, **412-413**
- Nonsteroidal antiinflammatory drugs, **403-411**, 439, 440f
- Actions, 405f
- for diarrhea, 244
- for migraine, 428
- and prostaglandins, 401
- summary, 412f
- Nonsteroidal antiinflammatory drugs, specific agents**, 401f
- aspirin, 13, 140, 193f, 196, 196, **196**, 201f, 211, 213, 244, 244f, 401f, 403, **403-408**, 404f-405f, 407f, 412f, 427f, 428, 439-440
- diclofenac (VOLTAREN), 401f, **411**, 411
- diflunisal (DOLOBID), 401f, 403, 403, 406, 408, 412f
- etodolac (LODINE), 401f, 409, **410**
- fenamates, 401f, **410**, 412f
- fenoprofen, 327, 401f, 408, **408-409**, 412f
- flurbiprofen (ANSAID), 401f, 408, **408-409**
- ibuprofen (ADVIL, MOTRIN), 401f, 408, **408-409**, 412f, 440
- indomethacin, 244, 244f, 401f, **409**, 409, 409f, 412f, 417
- ketoprofen (ORUDIS), 401f, 408, **408-409**, 412f, 417
- methylsalicylate, 401f, 406, 408
- nabumetone (RELAFEN), 401f, **411**, 411
- phenylbutazone, 201f, 260f, 401f, 410, **410-411**, 411f-412f
- piroxicam (FELDENE), 401f, **410**, 410, 412f
- sulindac (CLINORIL), 401f, 409, **410**, 412f
- tolmetin, 401f, **411**, 411, 412f
- NORDETTE. *See* Ethinyl estradiol
- Norepinephrine, **33**, 55f, **64**, 64, 69f
- adrenergic neurons and, 55
- and adrenergic receptors, 58f, 58-59
- and amine nitrogen, 61
- in autonomic nervous system, 32f
- binding, 56, 57f
- cardiovascular effects, 64f
- as direct-acting agonist, 61
- effect on blood pressure, 72f
- guanethidine and, 79
- indirect-acting agonists and, 61
- metabolism, 57f
- recapture, 56
- release, 56, 57f
- removal, 56, 57f
- reserpine and, 78
- sites of action, 36f
- storage, 56, 57f
- structure, 61f
- synthesis, 55, 57f
- Norethindrone, 263f, 267, 267, 268
- Norfloxacin (NOROXIN), 323, 323, **324**, 325-326
- for urinary tract infections, 325f
- Norgestrel, 263f, 267, 267, 268
- implants, failure rate, 268f
- NORMODYNE. *See* Labetalol
- NOROXIN. *See* Norfloxacin
- NORPLANT. *See* Levonorgestrel
- Nortestosterone progestins, 267
- Nortriptyline (PAMELOR), 119, 119, 119f
- therapeutic advantages and disadvantages, 125f
- NORVASC. *See* Amlodipine
- Nystatin, 337f, **343**, 343
- Oat cell carcinoma, of lung, treatment, 396
- Obsessive-compulsive disorder, treatment, 122
- Octreotide, 247f, **250**, 250
- Ofloxacin (FLOXIN), **324**, 324, 325-326
- Oil of wintergreen, 406
- Omeprazole (PRILOSEC), 235f, 239, 239, 440
- to eliminate *Helicobacter pylori*, 236
- and gastric acid regulation, 237f
- Onchocerca volvulus* infection, treatment, 356, 360, 361f
- Ondansetron, 242f, 243, 243
- in combination therapy, 243f
- Opiates, for cough, specific agents, 217f
- Opioid agonist-antagonist, **140-141**
- Opioid agonists
- actions, 134f
- adverse effects, 137f
- moderate, **140**
- onset and duration of action, 139f
- Opioid antagonists, **133-142**, **141-142**
- actions, 134f
- Opioid antagonists, specific agents**, 133f
- naloxone, 117, 133f-134f, 140, 141, 141f, **141-142**
- naltrexone, 133f-134f, 142, **142**
- Opioid receptors, **133-135**
- Opioids, 107f, 116-117, **133-142**
- preanesthetic, 108
- Opioids, specific agents**, 133f
- buprenorphine, 133f, **141**, 141
- codeine, 133f-135f, 137, 140, **140**, 140f, 222, 427f
- fentanyl, 108, 108f, 116f, 117, 133f-135f, 137, 139, **139**, 139f
- heroin, 100f, 133f-134f, 137, 139, 140, **140**, 141f, 142
- meperidine, 133f, 135f, 138, **138-139**, 139f, 244, 338, 427f
- methadone, 135f, **139**, 139, 147
- morphine, 90f, 100f, 108f, 117, 133f-135f, **135-138**, 139, 139f, 141, 141f, 142
- pentazocine, 133f-134f, 141, **141**
- propoxyphene (DARVON COMP 65, DARVOCET-N-100), 133f, 135f, 140, **140**, 148f, 428
- sufentanil, 133f, 139, 139
- Oral administration, drug, **2**, 3f
- kinetics, 20, 21f
- Oral contraception
- drug interactions, 147
- failure rate, 268f
- percent use, 268f
- Oral surgery, antibiotics in, 300
- ORASONE. *See* Prednisone
- Organic nitrates, for angina, **175-176**
- specific agents, 175f
- ORUDIS. *See* Ketoprofen
- Osmotic diuretics, 223f, **233**
- Osteoarthritis

- of hip, treatment, 409
treatment, 275, 408, 410-411
- Osteogenic sarcoma, 379
- Osteoporosis
senile, treatment, 270
treatment, 3
- Ovarian cancer, treatment, 382, 392, 395
- OVCON. *See* Ethinyl estradiol
- Oxacillin, 298*f*, 300, 300
stability to penicillinase, 300*f*
- Oxaprozin (DAYPRO), 401*f*, 408, 408-409
- Oxazepam, 91
for alcohol withdrawal, 91
duration of action, 92*f*
therapeutic advantages and disadvantages, 97*f*
- Oxazosin, for hypertension, 189
- Oxicam derivatives, 410
therapeutic advantages and disadvantages, 412*f*
- Oxymetazoline, 221
for rhinitis, 221
- Oxytocin, 247*f*, 250, 251, 251
- Paclitaxel, 373*f*, 391, 391-392, 392*f*, 399*f*
- PAMELOR. *See* Nortriptyline
- Pancreatic cancer, treatment, 382
- Pancuronium, 45*f*
onset and duration of action, 52*f*
pharmacokinetics, 51
therapeutic disadvantages, 52*f*
- Panic disorders, treatment, 120, 122
- Para-aminobenzoic acid (PABA), 289
structure, 290*f*
- Paramethasone, properties, 275*f*
- Parasympathetic nervous system, 27*f*, 29*f*, 30, 30*f*
- Parasympathetic neurons, 28
- Parenteral administration, 2-3
- Parkinsonism, secondary, 84
- Parkinson's disease
etiology, 83-84
treatment, 81-88
- Paromomycin, 345*f*, 348, 348
sites of action, 346*f*
- Paroxetine (PAXIL), 119*f*, 123, 123
therapeutic advantages and disadvantages, 125*f*
- Patent ductus arteriosus, treatment, 406, 409
- PAXIL. *See* Paroxetine
- Pectin, 244, 244*f*
- Pencyclovir, 367, 367
- D-Penicillamine, 402*f*, 414, 414
- Penicillinases, drug interactions, 300
- Penicillin-binding proteins, 298, 302
- Penicillin G, 298*f*, 300
absorption, 302
adverse reactions, 303
bioavailability, 7
metabolism, 302
stability to acid, 300*f*
substitutes for, 304
- Penicillins, 282*f*, 297, 297-303, 318*f*, 434-435
administration route, 2
antipseudomonal, 300*f*, 301
adverse reactions, 303
antistaphylococcal, 300, 300*f*
diffusion, 281*f*
distribution, 302, 303*f*
drug interactions, 315, 417
for enterococcal endocarditis, 284*f*
extended spectrum, 300, 300*f*
for listeriosis, 299*f*
natural, 300, 300*f*
resistance to, 301-302
safety, 282
therapeutic index, 22-23, 23*f*
- Penicillins, specific agents, 298*f***
amoxicillin (AMOXIL, POLYMOX, TRIMOX, WYMOX), 235*f*, 236, 282, 282*f*, 298*f*, 300, 300, 300*f*, 302, 308, 308*f*, 328*f*
ampicillin (PRINCIPEN), 283, 290, 298*f*-299*f*, 300, 300, 300*f*, 301-302, 328*f*, 435
azlocillin, 298*f*, 300*f*, 301, 301, 302
carbenicillin, 298*f*, 300*f*, 301, 301, 301*f*, 302-303
cloxacillin, 298*f*, 300, 300, 300*f*
dicloxacillin, 298*f*, 300, 300, 300*f*
methicillin, 285, 298*f*, 300, 300, 300*f*, 302
mezlocillin, 298*f*, 300*f*, 301, 301, 302
nafcillin, 298*f*, 300, 300, 300*f*, 303
oxacillin, 298*f*, 300, 300, 300*f*
penicillin G, 7, 298*f*, 300, 300*f*, 302-304
penicillin V (PEN-VEE K, VEETIDS, BETAPEN VK), 298*f*, 300, 300*f*, 302
piperacillin, 298*f*, 300*f*, 301, 301, 301*f*, 302
ticarcillin, 298*f*, 300*f*, 301, 301, 301*f*, 302-303
- Penicillin V (PEN-VEE K, VEETIDS, BETAPEN VK), 298*f*, 300
administration route, 302
stability to acid, 300*f*
- Penicillium chrysogenum, and penicillin formation, 300
- Pentamidine, 345*f*, 353*f*
drug interactions, 339, 370
for leishmaniasis, 356
- Pentamidine isethionate, 354, 354-355
- Pentazocine, 133*f*, 141, 141
action, 134*f*
- Pentobarbital, 90*f*, 94
duration of action, 95
preanesthetic, 108
therapeutic advantages and disadvantages, 97*f*
- PEN-VEE K. *See* Penicillin V
- PEPCID. *See* Famotidine
- Peptic ulcers, treatment, 235-241, 241, 282, 282*f*, 420
specific agents, 235*f*-236*f*
- Pepto-Bismol. *See* Bismuth subsalicylate
- Peripheral arterial thrombosis, treatment, 201
- Peripheral nervous system, 27, 27*f*
afferent division, 27, 27*f*
efferent division, 27, 27*f*
- Peripheral vascular disease, treatment, 189
- Pernicious anemia, treatment, 205
- PERSANTINE. *See* Dipyridamole
- Petit mal seizures. *See* Absence seizures
- pH, and drug absorption, 4-5, 6*f*
- Pharmacokinetics, 17-26
- Phase I reactions, 13-14, 14*f*
- Phase II reactions, 14*f*, 14-15
- Phenacetin, 401*f*, 412, 412-413
- Phencyclidine (PCP), 99*f*, 105, 105
dependence potential, 100*f*
opioid receptors and, 133
- Phenelzine, 119*f*, 123, 123
drug interactions, 86
therapeutic advantages and disadvantages, 125*f*
- PHENERGAN. *See* Promethazine
- Phenformin, 261
- Phenobarbital, 90*f*, 94, 143*f*, 438
as anticonvulsant, 95
drug interactions, 213, 343, 347
duration of action, 95
overdose, 23-24
primidone and, 148, 148*f*
ratio of lethal to effective dose, 90*f*
for seizures, 145*f*
therapeutic advantages and disadvantages, 97*f*
and thyroid hormone metabolism, 253
- Phenolphthalein, as laxative, 244, 244*f*
- Phenothiazines, 127*f*
antiemetic potency, 243*f*
for chemotherapy-induced nausea and

- vomiting, 242, 242f
 in combination therapy, 243
 drug interactions, 138
 and parkinsonism symptoms, 84
 and physostigmine, 42
 therapeutic advantages and disadvantages, 422f
- Phenoxybenzamine, 71, 71f, 71-72, 72f
- Phentolamine, 71f, 72, 72
 for hypertension, 124
- Phenylbutazone, 401f, 410, 410-411
 adverse effects, 411f
 drug interactions, 201f, 260f
 therapeutic advantages and disadvantages, 412f
- Phenylephrine (ENTEX LA), 55f, 66, 66, 69f
 and adrenergic receptors, 58
 with anesthesia, 113
 as direct-acting agonist, 61
 as non-catecholamine, 60
 in ophthalmic therapy, 47
 for rhinitis, 221
 structure, 60f
- β -Phenylethylamine, structure, 61f
- Phenylethylmalonamide, primidone and, 148, 148f
- Phenytoin (DILANTIN), 143f, 146, 146-147
 for arrhythmias, 174
 drug interactions, 147f, 150, 239, 295, 333, 341, 362, 408f
 metabolism, 13
 and plasma concentration, 146, 146f
 for seizures, 145f
 and thyroid hormone metabolism, 253
- Pheochromocytoma
 diagnosis, 72
 treatment, 72
- Phosphodiesterase inhibitors, 151f
 for congestive heart failure, 161, 161f
- Physostigmine, 35f, 42, 42
 and atropine, 47
 drug interactions, 51
- Phytonadione. *See* Vitamin K
- Pilocarpine, 35f, 41, 41
 actions, 41f
 for glaucoma, 75, 227
 structure, 39f
- Pindolol, 71f, 77, 77, 79f
 as antiarrhythmic, 171
 contraindication, 177
 drug elimination, 74f
- Pinworm infection, 360f
 treatment, 359, 361f
- Pipecuronium, 45f
 onset and duration of action, 52f
- Piperacillin, 298f, 301, 301
 administration route, 302
 stability
 to acid, 300f
 to penicillinase, 300f
 therapeutic applications, 301f
- Piperazines, therapeutic advantages and disadvantages, 422f
- Piperidines, therapeutic advantages and disadvantages, 422f
- Pirbuterol, for asthma, 218
- Pirenzepine, 236f, 240
 and gastric acid regulation, 237f
 and gastrointestinal problems, 46
 and muscarinic receptors, 38
- Piroxicam (FELDENE), 401f, 410, 410
 therapeutic advantages and disadvantages, 412f
- Pituitary dwarfism, treatment, 270
- Pituitary hormones, 247-254
- Plague, treatment, 315
- Plasma lipoproteins, metabolism, 208f
- Plasma proteins, binding of drugs to, 11-12
- Plasmodium falciparum infection, 349
 chloroquine-resistant, 351
 treatment, 349, 351-353
- Plasmodium, life cycle, 350f
- Plasmodium malariae infection, 349
 treatment, 353
- Plasmodium ovale infection, 349
 treatment, 349
- Plasmodium vivax infection, 349, 432, 432f
 treatment, 349, 351
- Platelet activation, 194-196, 195f
- Platelet aggregation, 195-196
- Platelet inhibitors, 196-197
- Platelet inhibitors, specific agents, 193f**
 aspirin, 13, 140, 193f, 196, 196, 196, 201f, 211, 213, 244, 244f, 401f, 403, 403-408, 404f-405f, 407f, 412f, 427f, 428, 439-440
 dipyridamole (PERSANTINE), 193f, 196, 196
 ticlopidine, 193f, 196, 196
- Platelets, role in clotting, 193, 194f
- Plicamycin, 373f, 387, 387, 399f
- Pneumococcal pneumonia, treatment, 299f
- Pneumocystis carinii pneumonia, 294f
 treatment, 289-290, 335, 354-355
- Pneumonia
 mycoplasma, treatment, 312f, 318f
 pneumococcal, treatment, 299f
Pneumocystis carinii, 294f
 treatment, 289-290, 335, 354-355
 treatment, 315f, 433
- Poisoning, heavy metal, treatment, 414
- Polycyclic antidepressants, 119f, 119-121
 mechanism of action, 120f
 therapeutic advantages and disadvantages, 125f
- Polycythemia vera, for sickle cell disease, 206
- Polyethylene glycol, 244f, 245
- POLYMOX. *See* Amoxicillin
- Pork insulin, 257
- Postcoital contraception, 268
- Posterior pituitary hormones, 247f, 250-251
- Postganglionic neuron, 28
- Postmenopausal hormone therapy, 264, 265f
- Potassium channel blockers, 163f
- Potassium-sparing diuretics, 223f, 232-233
 and changes in urine composition, 232f-233f
- Pralidoxime, 35f
 and reactivation of acetylcholinesterase, 43, 43f
- PRAVACHOL. *See* Pravastatin
- Pravastatin (PRAVACHOL), 207f, 214, 214-215
 cardiac death rate with, 214f
 drug interactions, 213
- Praziquantel, 359f, 360-362, 362
 drug interactions, 362
- Prazosin (MINIPRESS), 71f, 73, 73, 180f
 for hypertension, 124, 189
- Prednisolone, 393
 properties, 275f
- Prednisone (DELTASONE, ORASONE), 373f, 399f, 438-439
 for asthma, 219
 in cancer therapy, 393, 393
 in chemotherapy, 276
 drug interactions, 334f, 397
 properties, 275f
- Preganglionic neuron, 28
- Pregnancy-induced hypertension, treatment, 78
- PREMARIN. *See* Estrogens
- Premature births, drug contraindications, 251
- Premenstrual edema, kidney function during, 226
- Premenstrual syndrome, treatment, 122
- PRILOSEC. *See* Omeprazole

- Primaquine, 345*f*, 349, **349-350**, 350*f*, 432-433
 adverse effects, 350, 351*f*
- Primidone, 143*f*, **148**, 148
 metabolism, 148*f*
 for seizures, 145*f*
- PRINCIPEN. *See* Ampicillin
- PRINIVIL. *See* Lisinopril
- Probenecid, 402*f*, **417**, 417
 drug interactions, 260*f*, 303, 408*f*
 for hyperuricemia, 415
- Probucol, 207*f*, 213, **213-214**
 mechanism of action, 213, 213*f*
- Procainamide, 163*f*, **168**, 168
 for arrhythmias, 171, 172*f*
 effects, 167*f*
- Procaine, 108*f*
 pharmacokinetic properties, 117*f*
 structure, 117*f*
- Procaine penicillin G, administration route, 302
- Procarbazine, 373*f*, 396, **396-397**, 399*f*
 myelosuppressive potential, 378*f*
- PROCARDIA XL. *See* Nifedipine
- Prochlorperazine (COMPazine), 127*f*, 242, 242, 242*f*
 antiemetic effects, 129*f*
 in combination therapy, 243
 for nausea, 129
- Progesterone, 266-267
 menstrual cycle and, 266, 267*f*
- Progestin implants, 268
- Progestins, **266-267**, 268
 failure rate, 268*f*
- Progestins, specific agents, 263*f***
 hydroxyprogesterone, 263*f*, 267, 267
 levonorgestrel, 3, 268, 269*f*
 medroxyprogesterone (PROVERA), 263*f*, 267, 267
 norethindrone, 263*f*, 267, 267, 268
 norgestrel, 263*f*, 267, 267, 268, 268*f*
- Pro-insulin, 257
- Prolactin-inhibiting hormone, actions, 248*f*
- Prolactin-releasing hormone, actions, 248*f*
- Promethazine (PHENERGAN), 127*f*, 130, 130
 actions, 128*f*
 antiemetic effects, 129*f*
 therapeutic advantages and disadvantages, 422*f*
- Propafenone, 163*f*, **170**, 170
 for arrhythmias, 171, 172*f*
 effects, 170*f*
- Prophylactic antibiotics, 286, 286*f*
- Propionic acid
 derivatives, **408-409**
 therapeutic advantages and disadvantages, 412*f*
- Propofol, 108*f*, **117**, 117
 therapeutic advantages and disadvantages, 116*f*
- Propoxyphene (DARVON COMP 65, DARVOCET-N-100), 133*f*, **140**, 140
 drug interactions, 148*f*
 efficacy and addiction/abuse liability, 135*f*
 for migraine, 428
- Propranolol (INDERAL), 71*f*, 74, **74-76**, 79*f*, 163*f*, 175*f*, 179*f*, 436-437
 actions, 75*f*
 adverse effects, 76*f*
 for angina, 176
 as antiarrhythmic, 164*f*, 171
 clinical applications, 78*f*
 drug interactions, 334*f*
 elimination, 74*f*
 with hydralazine, 190
 for hypertension, 185
 metabolism, 7
 for migraine, 427*f*, 428
- Propylthiouracil, 247*f*, 253, 253-254, 436
- Prostaglandin E1, 267
- Prostaglandins, **401-403**
 as autacoids, 419-420
 for peptic ulcer disease, 235*f*, 238-239
 specific agents, 419*f*
 structure, 402*f*
 synthesis, 403*f*
 therapeutic applications, 420*f*
- Prostaglandins, specific agents**
 carboprost, 419, **419**, 419*f*-420*f*
 dinoprost, 419, **419**, 419*f*-420*f*
 dinoprostone, 419, **419**, 419*f*-420*f*
 misoprostol, 235*f*, 237*f*, 238, 238-239, 267, 267, 380, 407, 419, 419*f*, 420, 420, 420*f*
- Prostate
 cancer
 metastatic, treatment, 394
 treatment, 272, 394
 effect on endocrine system, 395*f*
 infections, 281
 treatment, 294*f*, 328*f*
- Prostatic hyperplasia, benign, treatment, 73, 272
- Prostatitis. *See* Prostate, infections
- Protamine sulfate, 193*f*, **204**, 204
 for excessive bleeding, 199
- Protamine zinc suspension, 255*f*
- Proteins
 binding of drugs to, 8-9
 drugs binding to, 8-9
- Protein synthesis inhibitors, **311-321**
 specific agents, 311*f*
- Proteus**
 infection (iodide positive), treatment, 301*f*, 315*f*
 resistance, 328
- Proteus mirabilis** infection, 327
 treatment, 294*f*, 301*f*, 304, 325*f*
- Proton pump inhibitors, for peptic ulcer disease, 235*f*, 239
- Proton pump inhibitors, specific agents**
 lansoprazole, 235*f*, 239, 239
 omeprazole (PRILOSEC), 235*f*, 236, 237*f*, 239, 239, 440
- Protriptyline, 119, 119, 119*f*
 therapeutic advantages and disadvantages, 125*f*
- PROVENTIL. *See* Albuterol
- PROVERA. *See* Medroxyprogesterone
- PROZAC. *See* Fluoxetine
- Pruritus, treatment, 130, 212
- Pseudomonas aeruginosa** infection, 430-431
 treatment, 301, 301*f*, 304, 305*f*, 307, 315*f*, 324, 325*f*
- Pseudomonas** infection, treatment, 324
- Psittacosis, treatment, 312*f*
- Psychomotor stimulants, **99-104**
 specific agents, 99*f*
- Psychotomimetic drugs, specific agents, 99*f***
 lysergic acid diethylamide (LSD), 99*f*-100*f*, **105**
 phencyclidine (PCP), 99*f*-100*f*, 105, **105**, 133
 tetrahydrocannabinol (THC), 99*f*, **105**, 105, 243
- Psyllium seeds, 244*f*, 245
- PTU. *See* Propylthiouracil
- Pulmonary edema, acute, treatment, 228
- Pulmonary embolism
 acute, treatment, 203
 massive, treatment, 202
 treatment, 198, 201, 203
- Purkinje fiber, action potential, 152*f*
- Pyelonephritis, acute, treatment, 328*f*
- Pyrantel pamoate, 359, 359*f*, **359-360**, 361*f*
- Pyrazinamide, 331, **334**, 334, 437
 adverse effects, *f*, 335
 drug interactions, 334
 for tuberculosis, 284*f*
- Pyrazoles, therapeutic advantages and disadvantages, 412*f*

- Pyridostigmine, 35*f*, **42**, 42
- Pyridoxine, drug interactions, 86*f*
- Pyrilamine, therapeutic advantages and disadvantages, 422*f*
- Pyrimethamine, 289*f*, 290, 290, 345*f*, 350*f*, 357
- as folate reductase inhibitor, 293
 - for malaria, 352-353
 - for toxoplasmosis, 357
- Quazepam
- duration of action, 92*f*
 - therapeutic advantages and disadvantages, 97*f*
 - withdrawal reactions, 93*f*
- QUESTRAN. *See* Cholestyramine
- Quinacrine, 345*f*
- for giardiasis, 357
- Quinapril (LOTENSIN), 151*f*, 179*f*
- Quinestrol, 263, 263, 263*f*
- Quinidine, 163*f*, 167, **167-168**, 169, 345*f*
- antiarrhythmic effects, 164*f*, 171, 172*f*
 - drug interactions, 147, 160*f*, 169, 214, 334*f*
 - effects, 167*f*
- Quinidine sulfate, 168
- Quinine, 345*f*, 350*f*, **352**, 352
- Quinolones, **323-330**
- specific agents, 323*f*
- Ramipril (ACCUPRIL, ALTACE), 179*f*
- Ranitidine (ZANTAC), 235*f*, 236, **236-238**, 419*f*, 438, 440
- Raynaud's disease, treatment, 72
- Rectal administration, **2**
- Reentry, 165, 165*f*
- REGLAN. *See* Metoclopramide
- Regulation, with second messenger molecules, 34
- RELAFEN. *See* Nabumetone
- Renal disease
- anemia with, treatment, 206
 - chronic
 - and angina, 178*f*
 - and hypertension, 182*f*-183*f*
- Renal elimination, **23-24**, 24*f*
- Renal failure, acute, treatment, 233
- Renin-angiotensin-aldosterone system, and blood pressure, 180-181, 181*f*
- Reserpine, 71*f*, **78**, 78
- and norepinephrine storage, 56
- Respiratory infections, 294*f*
- lower, treatment, 324
 - treatment, 300, 325*f*
 - specific agents, 363*f*
 - viral, treatment, **363-365**
- Respiratory syncytial virus, treatment, 365
- Respiratory system, drugs affecting, **217-222**
- specific agents, 217*f*
- RESTORIL. *See* Temazepam
- Rheumatic fever, treatment, 406
- Rheumatoid arthritis
- acute, treatment, 410
 - intractable, treatment, 389
 - treatment, 351, 406, 408, 410-411, 413-415
- Rheumatoid inflammations, treatment, 275
- Rhinitis
- causes, 220, 221*f*
 - drug treatment, specific agents, 217*f*
 - treatment, **220-221**
- Rhythm method, of contraception, failure rate, 268*f*
- Ribavirin, 363*f*, 364, **364-365**
- Rifabutin, 333
- for Kaposi's sarcoma, 429
- Rifampin, 331, 331*f*, 333, **333-334**, 437
- classification, 287*f*
 - drug interactions, 201*f*, 334, 340-341
 - for methicillin-resistant staphylococcus aureus, 300
 - resistance to, 285, 285*f*
 - and thyroid hormone metabolism, 253
 - for tuberculosis, 284*f*
- Rimantadine, 363, 363*f*, **363-364**
- Risperidone, 127*f*, 128, 128, 130-131, 132*f*
- actions, 128*f*
- RITALIN HYDROCHLORIDE. *See* Methylphenidate
- Ritodrine, 55*f*, 69*f*
- Ritonavir, **371**, 371
- River blindness, treatment, 360, 361*f*
- Rocky Mountain spotted fever, treatment, 312*f*
- Rocuronium, 45*f*
- onset and duration of action, 52*f*
 - pharmacokinetics, 51
 - therapeutic advantages, 52*f*
- ROGAINE. *See* Minoxidil
- Roloids. *See* Calcium carbonate
- Roundworm infection, treatment, 359, 361*f*
- RU 486. *See* Mifepristone
- Salicylates, **403-408**
- dose-dependent effects, 406*f*
 - drug interactions, 260*f*, 408*f*
 - therapeutic advantages and disadvantages, 412*f*
- Salicylate salts, therapeutic advantages and disadvantages, 412*f*
- Salicylic acid, 406
- Salmeterol xinaoate
- for asthma, 218, 218
 - and bronchodilation, 67*f*
- Salmonella infection
- non-typhoid, treatment, 294*f*
 - treatment, 289, 291
- Salmonella typhi infection, treatment, 294*f*
- Saquinavir, **371**, 371
- Sarcoma. *See also* Kaposi's sarcoma
- Ewing's soft tissue, 390
 - osteogenic, 379
 - soft tissue, treatment, 384
 - treatment, 386
- Schizonticides
- blood, for malaria, 351-353
 - tissue, for malaria, 349-350
- Schizophrenia, **127**
- rates of relapse, 131*f*
 - treatment, 129, 131
- Scopolamine, 45*f*, **48**, 48, 48*f*-49*f*, 438
- antiemetic effects, 129*f*
 - for motion sickness, 130, 242
 - and muscarinic receptor, 46*f*
 - preanesthetic, 108
- Secobarbital, 90*f*, 94
- duration of action, 95
 - therapeutic advantages and disadvantages, 97*f*
- Second messenger systems, **33-34**
- Seizures
- absence, **144**, 144*f*-145*f*
 - treatment, 149
 - classification, 144*f*, **144-145**
 - complex partial, **144**, 144*f*-145*f*
 - treatment, 146-147, 150
 - febrile, **144**, 144*f*-145*f*
 - treatment, 148
 - generalized, 144*f*, **144-145**, 145*f*
 - grand mal. *See* Seizures, tonic-clonic
 - myoclonic, **144**, 144*f*-145*f*
 - treatment, 149
 - partial, **144**, 144*f*-145*f*
 - treatment, 146-150
 - petit mal. *See* Seizures, absence
 - simple partial, **144**, 144*f*-145*f*
 - treatment, 146-148, 150
 - tonic-clonic, **144**, 144*f*-145*f*, 148
 - treatment, 91, 146-150
 - treatment, 90-91, 95
- SELDANE. *See* Terfenadine
- Selegiline, 81*f*
- Semilente insulin, 255*f*
- extent and duration of action, 259*f*
- Semilente insulin suspension, **258**

- Senna, 244, 244*f*
- Sermorelin, 247*f*, 249, 249
- Serotonin antagonists, antiemetic potency, 243*f*
- Serotonin reuptake inhibitors, 119*f*, **122-123**
 receptor specificity, 121*f*
 therapeutic advantages and disadvantages, 125*f*
- Serratia marcescens* infection, treatment, 304, 315*f*, 325*f*
- Sertraline (ZOLOFT), 119*f*, 123, 123
 therapeutic advantages and disadvantages, 125*f*
- Serum lipoprotein, 207, 208*f*
 drugs that lower concentration, **210-215**
- Sevoflurane, 107*f*, **115**, 115
- Shigella* infection (shigellosis), treatment, 291, 294*f*, 325*f*
- Shock
 blood flow with, 5-6
 treatment, 64-66, 69
- Sickle cell disease (anemia)
 specific agent for, 193*f*
 treatment, 206
- Silver sulfadiazine, 289*f*
 for burns, 291
 therapeutic application, 290
- Simvastatin (ZOCOR), 207*f*, 214, **214-215**
- SINEMET. *See* Carbidopa
- Skin infections, treatment, 324
- Sleep disorders, treatment, 91
- SLO-BID. *See* Theophylline
- SLOW-K. *See* Potassium
- Smooth muscle
 effects of nitrites and nitrates on, 176, 176*f*
 relaxants, direct, **157**
- Sodium bicarbonate, 236*f*, 240
- Sodium channel blockers, 163*f*
- Sodium nitroprusside, 151*f*, 180*f*, **191**, 191
- Sodium pentothal, with anesthesia, 110
- Sodium salicylate, 406
- Sodium stibogluconate, 345*f*, 356, **356-357**
- Soft tissue sarcomas, treatment, 384
- Solid tumors, treatment, 388
- Somatic nervous system, 27*f*, **31**, 32*f*
 cholinergic agonists in, 36*f*
- Somatostatin, 247*f*, **250**
 actions, 248*f*
- Somatotropin, 247*f*, **249**, 249
- Somatrem, 247*f*, 249, 249
- Sotalol, 163*f*, 171, **171-172**
 antiarrhythmic effects, 164*f*
 drug interactions, 214
- Spacer, for asthma, 219, 220*f*
- Spectinomycin, 311*f*
 for gonorrhea, 299*f*
- Spermicide
 failure rate, 268*f*
 percent use, 268*f*
- Spirochetes, 283*f*
- Spirolactone, 179*f*, 183, 183, 223*f*, **232-233**, 233
 as adrenocorticoid inhibitor, 277
 for hyperaldosteronism, 274
 site of action, 224*f*
- Sporontocide, blood, 353
- Squamous cell carcinoma
 of head and neck, treatment, 392
 treatment, 387
- Stanozolol, 263*f*, 271, 271
- Staphylococcal infections, treatment, 308
- Staphylococcus aureus* infection, 435
 methicillin-resistant, 298, 300, 304, 308, 429-430
 resistance, 285
 treatment, 299*f*, 306
- Staphylococcus epidermiditis* infection, methicillin-resistant, 308
- Staphylococcus saprophyticus* infection, 327
- Status epilepticus, 144*f*, **145**, 145*f*
 treatment, 91, 95, 146, 149
- Stavudine (d4T), 363*f*, 369*f*, **370**, 370
- Steady-state, 17*f*, **17-19**, 18*f*-19*f*
- Sterilization, contraceptive
 failure rate, 268*f*
 percent use, 268*f*
- Steroid antagonists, in cancer therapy, 392-395
 specific agents, 373*f*
- Steroid hormones, **263-278**
 for cancer, 392-395
 specific agents, 373*f*
 mechanism of action, 393*f*
 specific agents, 263*f*-264*f*
- Stool softeners, 245
- Streptococcus pneumoniae* infection, treatment, 294*f*, 299*f*
- Streptococcus pyogenes* infection, treatment, 299*f*
- Streptococcus viridans* infection, 434
 treatment, 299*f*
- Streptokinase, 193*f*, 201, 202, **202-203**, 204*f*
 activation of plasminogen, 202*f*
 mechanism of action, 202, 203*f*
 properties, 202*f*
- Streptomyces*, aminoglycosides from, 314
- Streptomycin, 311*f*, 314, 314, 331
 antibacterial spectrum, 315
 therapeutic applications, 315*f*
- Streptozocin, emetic potential, 241*f*
- Streptozotocin, 373*f*
- Stress ulcers, acute, treatment, 237
- Stroke, treatment, 72
- Strongyloides stercoralis* infection (strongyloidiasis), 361*f*
 treatment, 360, 361*f*
- Subcutaneous (SC) administration, **3**
- Sublingual administration, **2**
- Substance abuse, potential for, 100*f*
- Substituted benzamides
 antiemetic potency, 243*f*
 for chemotherapy-induced nausea and vomiting, 242*f*
- Substituted benzodiazepines, for chemotherapy-induced nausea and vomiting, 242
- Succinylcholine, 45*f*, 53, **53**, 53*f*, 107*f*
 adverse effects, 53
 with anesthesia, 109
 onset and duration of action, 52*f*
 therapeutic disadvantages, 52*f*
- Succinylsulfathiazole, 289*f*, 291
 administration, 291
- Sucralfate (CARAFATE), 236*f*, **241**, 241
 drug interactions, 341
- Sufentanil, 133*f*, 139, 139
- Sulbactam, 298*f*, 307, 307
 administration route, 302
 drug interactions, 300
 stability to penicillinase, 300*f*
- Sulfacetamide, 289*f*
 therapeutic application, 290
- Sulfadiazine, 289*f*, 290, 290, 292
 therapeutic application, 290
- Sulfadoxine, for malaria, 352
- Sulfamethoxazole, 289, 289, 289*f*, 290.
See also Co-trimoxazole
 antimicrobial activity rate, 293*f*
 drug interactions, 293
 mechanism of action, 294
 for urinary tract infection, 315*f*
- Sulfanilamide, 289, 289
 mechanism of action, 292*f*
- Sulfapyridine
 in inflammatory bowel disease, 291
 metabolism, 291
- Sulfasalazine, 289*f*, 291
 administration, 291
 metabolism, 291

- Sulfinpyrazone, 402*f*, **417**, 417
 drug interactions, 408*f*
 for hyperuricemia, 415
- Sulfisoxazole, 289*f*, 292, 292
 therapeutic application, 290
 for urinary tract infections, 328*f*
- Sulfonamides
 classification, 287*f*
 drug interactions, 147, 147*f*, 260*f*
 effect on neonates, 282
 and folate inhibition, 290
 inactivation, 291
 for malaria, 352
 mechanism of action, 292*f*
 resistance to, 285*f*
- Sulfonamides, specific agents**
 mafenide, 289*f*, 290
 mafenide acetate, 291
 silver sulfadiazine, 289*f*, 290-291
 succinylsulfathiazole, 289*f*, 291, 291
 sulfacetamide, 289*f*, 290
 sulfadiazine, 290
 sulfamethoxazole, 289, 289, 289*f*, 290, 293, 293*f*, 294, 315*f*. *See also* Co-trimoxazole
 sulfasalazine, 289*f*, 291, 291
 sulfisoxazole, 289*f*, 290, 292, 292, 328*f*
- Sulfonyleureas, **260-261**
 drug interactions, 260*f*, 292, 334*f*
- Sulindac (CLINORIL), 401*f*, 409, **410**
 therapeutic advantages and disadvantages, 412*f*
- Sumatriptan (IMITREX), 419*f*, 426, **426-427**, 437
 for migraine, 427*f*
- SUMYCIN. *See* Tetracycline
- Supraventricular tachyarrhythmia
 concomitant with hypertension, treatment, 185
 treatment, 187, 188*f*
- Supraventricular tachycardia
 acute, treatment, 164*f*
 treatment, 66, 78*f*, 164*f*, 172-173
- SUPRAX. *See* Cefixime
- Suramin, 345*f*, 353*f*, **356**, 356
- Sympathetic nervous system, 27*f*, 29*f*, 29-30, 30*f*
 and blood pressure, 180, 181*f*
- Sympathetic neurons, **28**
- SYNTHROID. *See* Levothyroxine
- Syphilis, treatment, 299*f*, 318*f*
- TAGAMET. *See* Cimetidine
- Tamoxifen (NOLVADEX), 263*f*, **266**, 266, 373*f*, 399*f*
 in cancer therapy, 393, **393-394**
- Tapeworm infection, treatment, 362
- TAVIST. *See* Clemastine
- Taxol, 373*f*
- Tazobactam, 298*f*, 307, 307
 administration route, 302
 drug interactions, 301
 stability to penicillinase, 300*f*
- 3TC. *See* Lamivudine
- TEGRETOL. *See* Carbamazepine
- Temazepam (RESTORIL), 91
 duration of action, 92*f*
 for sleep disorders, 92
 therapeutic advantages and disadvantages, 97*f*
 withdrawal reactions, 93*f*
- Teniposide, **396**, 396
- TENORMIN. *See* Atenolol
- Tension headache, characteristics, 425*f*
- Terazosin (HYTRIN), 71*f*, **73**, 73, 180*f*
 for hypertension, 189
- Terbutaline, 55*f*, **67**, 67, 69*f*
 for asthma, 62-63, 218
 and bronchodilation, 67*f*
- Terfenadine (SELDANE)
 drug interactions, 214, 320, 341
 for rhinitis, 221
 therapeutic advantages and disadvantages, 422*f*
- Testicular carcinoma
 metastatic, treatment, 395
 refractory, treatment, 396
- Testicular tumors, treatment, 386, 399*f*
- Testosterone, 269, 269-271
 production, 272*f*
 secretion, regulation, 270*f*
 synthesis, suppression, 340
- Testosterone cypionate, 263*f*, 271, 271
- Tetracaine, 108*f*
 pharmacokinetic properties, 117*f*
- Tetracycline (SUMYCIN), 235*f*, 283, 283*f*, 311*f*, 345-346
 classification, 287*f*
 contraindications, 282
 cost, 282, 282*f*
 drug interactions, 160*f*, 213, 240
 to eliminate *Helicobacter pylori*, 236
 phototoxicity, 314
 resistance to, 285*f*
 sites of action, 346*f*
- Tetracyclines, 311, **311-314**
 absorption, 313, 313*f*
 adverse effects, 314*f*
 effect on children, 282
 for listeriosis, 299*f*
 therapeutic applications, 290, 312*f*
 for urinary tract infections, 328*f*
- Tetracyclines, specific agents**, 311*f*
 demeclocycline, 311*f*, 314, 314
 doxycycline (VIBRAMYCIN), 147, 311*f*-312*f*, 313, 313, 314, 328*f*
 minocycline (MINOCIN), 311*f*, 313, 313, 314
 tetracycline (SUMYCIN), 160*f*, 213, 235*f*, 236, 240, 282, 282*f*, 283, 283*f*, 285*f*, 287*f*, 311*f*, 314, 345-346, 346*f*
- Tetrahydrocannabinol (THC), 99*f*, **105**, 105
 for chemotherapy-induced nausea and vomiting, 243
- 6-TG. *See* 6-Thioguanine
- Theobromine, 99, 99*f*
- THEO-DUR. *See* Theophylline
- Theophylline (SLO-BID, THEO-DUR), 99, 99*f*, **220**
 for asthma, 100, 217*f*
 for chronic obstructive pulmonary disease, 222
 drug interactions, 319-320, 326, 395
- Therapeutic equivalence, 7
- Therapeutic index, 22*f*, 22-23
- Thiabendazole, 359*f*, **360**, 360, 361*f*
- Thiamylal, 108*f*, 115
- Thiazide diuretics, 157, 223*f*, 228-231
 adverse effects, 230*f*, 230-231
 for angina, **183-184**
 actions, 183*f*
 and changes in urine composition, 229*f*, 233*f*
 drug interactions, 160, 160*f*, 213, 292, 409
 site of action, 224*f*
 therapy with, 441
- Thiethylperazine, antiemetic effects, 129*f*
- Thioamides, 253-254
- 6-Thioguanine, 373*f*, 380, **382**, 382, 399*f*
 actions, 374*f*
- Thiopental, 90*f*, 94, 108*f*, 109
 as anesthetic, 95, 115-116
 distribution, 9
 drug interactions, 408*f*
 duration of action, 95
 redistribution, 115, 115*f*
 therapeutic advantages and disadvantages, 97*f*, 116*f*
- Thioridazine, 127*f*, 129, 129, 132*f*
 actions, 128*f*
 anticholinergic activity, 130
- Thiothixene, 127, 127, 127*f*, 132*f*
 actions, 128*f*
- Thioxanthenes, 127*f*

- Threadworm infection, treatment, 360, 361*f*
- Thrombolytic agents, **201-204**
 adverse effects, 202, 203*f*
 comparison, 202*f*
 specific agents, 193*f*
- Thrombus, 194
- Thyroid
 drugs affecting, 247*f*
 removal, 253
- Thyroid hormones, **251-254**
 biosynthesis, 252*f*
- Thyroid-stimulating hormone, 252-253
- Thyroid storm, treatment, 254
- Thyrotoxicosis, treatment, 78*f*, 253-254
- Thyrotropin, 252-253
- Thyrotropin-releasing hormone, 252-253
 actions, 248*f*
- Thyroxine, 247*f*, 251
 biosynthesis, 252*f*
 drug interactions, 408*f*
- Ticarcillin, 298*f*, 301, 301
 administration route, 302
 adverse reactions, 303
 stability
 to acid, 300*f*
 to penicillinase, 300*f*
 therapeutic applications, 301*f*
- Ticlopidine, 193*f*, **196**, 196
- Timolol (TIMOPTOL, TIMOPTIC), 71*f*, **76**, 76, 79*f*, 179*f*
 clinical applications, 78*f*
 drug elimination, 74*f*
- TIMOPTIC. *See* Timolol
- TIMOPTOL. *See* Timolol
- Tissue-type plasminogen activator (tPA).
See Alteplase
- Tobramycin (TOBREX), 311*f*, 315, 315, 431
 adverse effects, 316
 concentration, 316*f*
 drug interactions, 51
 therapeutic applications, 315*f*
- TOBREX. *See* Tobramycin
- Tocainide, 163*f*, **170**, 170
 effects, 169*f*
- Tolazamide, 255*f*, 260, 260
 properties, 261*f*
- Tolbutamide, 255*f*, 260, 260
 adverse effects, 292
 drug interactions, 341
 properties, 261*f*
- Tolmetin, 401*f*, **411**, 411
 therapeutic advantages and disadvantages, 412*f*
- Topical administration, **3-4**
- Topoisomerase, 323, 324*f*
- TORADOL. *See* Ketorolac
- Torsemide, 223*f*, 227, **227-228**
 site of action, 224*f*
- Total body clearance, 24-25
- Toxoplasma gondii infection (toxoplasmosis), 357
 treatment, 290, 345*f*, 353, **357**
- Trachoma infections, 290*f*
- Tranexamic acid, 193*f*, **204**, 204
- Transdermal patch, nicotine concentration, 101*f*
- TRANSDERM-NITRO. *See* Nitroglycerin
- Transient ischemic attacks, treatment, 196, 406
- TRANXENE. *See* Clorazepate
- Tranlycypromine, 119*f*, 123, 123
 therapeutic advantages and disadvantages, 125*f*
- Trazodone, 96, 119*f*, 123, 123
 therapeutic advantages and disadvantages, 125*f*
- Trematodes, chemotherapy, 359*f*, **360-362**
- Treponema pallidum infection, treatment, 299*f*, 312*f*
- Treponema pertense infection, treatment, 299*f*
- Triacylglycerol, niacin for, 210
- Triamcinolone (AZMACORT), 276, 276
 administration route, 276*f*
 for asthma, 219
 elimination, 276*f*
 properties, 275*f*
 for rhinitis, 221
- Triamterene (DYAZIDE), 179*f*, 223*f*, **233**, 233
 site of action, 224*f*
- Triazolam (HALCION), 91
 duration of action, 92*f*
 for sleep disorders, 92
 therapeutic advantages and disadvantages, 97*f*
 withdrawal reactions, 92, 93*f*
- Trichinella spiralis infection, 361*f*
 treatment, 360
- Trichinosis, treatment, 360, 361*f*
- Trichomonas vaginalis infection, treatment, 347
- Trichophyton infection, treatment, 343
- Trichuris trichiura infection (trichuriasis), 361*f*
 treatment, 359, 361*f*
- Tricyclic antidepressants, 119*f*, **119-121**
 drug interactions, 122*f*, 138
 mechanism of action, 120*f*
 and physostigmine, 42
 receptor specificity, 121*f*
 therapeutic advantages and disadvantages, 125*f*
- Trifluridine, 363*f*, **368**, 368
- Trigeminal neuralgia, treatment, 147
- Trihexyphenidyl, for Parkinson's disease, 87-88
- Triiodothyronine, 247*f*, 251
 biosynthesis, 252*f*
 drug interactions, 408*f*
- TRI-LEVELIN. *See* Ethinyl estradiol
- Trimeprazine, therapeutic advantages and disadvantages, 422*f*
- Trimethaphan, 45*f*, 49, **49**, 49*f*
- Trimethoprim (BACTRIM), 289, 289, 289*f*, 290, **293**, 293. *See also* Co-trimoxazole
 antimicrobial activity rate, 293*f*
 for bacterial prostatitis, 281, 281*f*
 classification, 287*f*
 drug interactions, 289
 and folate deficiency, 205
 interaction with enzymes, 20
 mechanism of action, 292*f*, 293-294
 resistance to, 285, 285*f*
 for urinary tract infection, 315*f*
- Trimethoprim-sulfmethoxazole, for urinary tract infections, 328*f*
- Trimipramine, 119*f*
 therapeutic advantages and disadvantages, 125*f*
- TRIMOX. *See* Amoxicillin
- TRI-NORINYL. *See* Ethinyl estradiol
- Tripelennamine, therapeutic advantages and disadvantages, 422*f*
- TRIPHASIL. *See* Ethinyl estradiol
- Tripolidine, therapeutic advantages and disadvantages, 422*f*
- Trypanosoma brucei gambiense infection, 353, 353*f*
 treatment, 354
- Trypanosoma brucei rhodesiense infection, 353, 353*f*
 treatment, 354
- Trypanosoma cruzi infection, 353, 353*f*
 resistance, 355
 treatment, 355
- Trypanosomiasis
 chemotherapy, 345*f*, **353-356**
 summary, 353*f*
- Tuberculosis, 436-437. *See also* Mycobacterium tuberculosis infection

- chemotherapy, **332-335**
 incidence, 332f
 treatment, 284, 284f, 315, 331f
- Tubocurarine, 45f, 50, 50f, 50f
 drug interactions, 51
 and neostigmine, 42
 and nicotinic receptors, 39
 onset and duration of action, 52f
 pharmacokinetics, 51
 therapeutic disadvantages, 52f
- Tularemia, treatment, 315, 315f
- Tumors. *See also* Cancer; Testicular tumors
 growth rate, 374
 mass, 375f
 treatment-induced, 378
- Tums. *See* Calcium carbonate
- TYLENOL. *See* Acetaminophen
- Type I diabetes. *See* Diabetes mellitus, insulin-dependent
- Type II diabetes. *See* Diabetes mellitus, non-insulin-dependent
- Tyramine, 55f, **68**, 68
 as indirect-acting agonist, 61
- Tyrosine, in norepinephrine synthesis, 55
- Ultralente insulin, 255f, **259**
 extent and duration of action, 259f
- Urea, 223f, 233, 233
- Ureaplasma infection, 318f
 treatment, 317
- Ureaplasma urealyticum infection,
 treatment, 318f, 328f
- Urethral syndrome, acute, treatment, 328f
- Urethritis, treatment, 318
- Uric acid, in gout, 415, 415f
- Uricosuric agents, **417**
- Urinary tract antiseptics, **323-330**, **327-329**
- Urinary tract antiseptics, specific agents, 323f**
 methenamine, 292, 327, 327f, **327-328**
 nitrofurantoin (MACRODANTIN, MACRO-BID), **329**, 329
- Urinary tract infections, 290f
 treatment, 294f, 315f, 324, 328f
- Urofollitropin, **250**
- Urokinase, 193f, 201, **203**, 203, 204f
 activation of plasminogen, 202f
 properties, 202f
- Urticaria, treatment, 424
- Uveitis, treatment, 409
- Vaginal infections, treatment, 294f
- VALIUM. *See* Diazepam
- Valproic acid (DEPAKOTE), 143f, 148, **148-149**
 adverse effects, 149f
 drug interactions, 150
 for seizures, 145f
- VANCENASE. *See* Beclomethasone
- VANCERIL. *See* Beclomethasone
- Vancomycin, 298f, 308, **308-309**, 429-431, 434-435
 classification, 287f
 for methicillin-resistant staphylococcus aureus, 300
 resistance to, 284, 285f
- Varicella-zoster virus, treatment, 367
- Vascular trauma, normal response to, 193-194
- Vasodilators, **155-157**
 for hypertension, 190-191
- Vasodilators, specific agents, 151f**
- Vasopressin, 247f, 250, **251**, 251
- VASOTEC. *See* Enalapril
- Vecuronium, 45f, 107f
 with anesthesia, 109
 onset and duration of action, 52f
 pharmacokinetics, 51
 therapeutic advantages, 52f
- VEETIDS. *See* Penicillin V
- Venlafaxine, 119f, 123, 123
 therapeutic advantages and disadvantages, 125f
- Venous thromboembolism, treatment, 198
- Venous thrombosis, treatment, 198
- VENTOLIN. *See* Albuterol
- Ventricular arrhythmias, treatment, 169-170, 172
- Ventricular fibrillation, treatment, 164f, 172
- Ventricular tachyarrhythmia, treatment, 168, 170, 172
- Ventricular tachycardia
 acute, treatment, 164f
 treatment, 164f, 171-172
- Verapamil (ISOPTIN, VERELAN), 163f, 167, **173**, 173, 175f, **177**, 177, 180f, 187, 187
 actions, 187f
 adverse effects, 189
 for angina, 188f
 as antiarrhythmic, 164f
 drug interactions, 160f, 169, 377
 effects, 173f
 for hypertension, 188f
 for supraventricular tachyarrhythmia, 188f
- VERELAN. *See* Verapamil
- VIBRAMYCIN. *See* Doxycycline
- Vibrio cholerae infection, treatment, 312f, 315f
- Vidarabine (ara-A), 363f, 367, 367f, **367-368**
- Vinblastine, 373f, 390, **390-391**, 399f
 drug interactions, 386, 395
 myelosuppressive potential, 378f
- Vincristine, 373f, 390, **390-391**, 399f
 drug interactions, 384, 397
 emetic potential, 241f
 myelosuppressive potential, 378f
- Vinorelbine, 390, 390
- Viral infections, treatment, 412
- Visceral leishmaniasis, 356
- Vitamin B₁₂. *See also* Cyanocobalamin deficiency, as similar to folate deficiency, 205
- Vitamin K, 193f, **204**
 for bleeding, 204
 and warfarin, 200
- VOLTAREN. *See* Diclofenac
- Vomiting. *See also* Emesis
 mechanisms that trigger, 241-242
 treatment, 129-130
- Warfarin (COUMADIN), 193f, 199, **199-201**
 adverse effects, 292
 drug interactions, 188, 196, 201f, 213, 239, 295, 320, 326, 334f, 341, 411
 mechanism of action, 200, 200f
 therapeutic index, 22f, 22-23
- Whipworm infection, treatment, 359, 361f
- Wilm's tumor, 390
 treatment, 384, 399f
- Withdrawal method, of contraception
 failure rate, 268f
 percent use, 268f
- Wucheria bancrofti, 361f
- WYMOX. *See* Amoxicillin
- XANAX. *See* Alprazolam
- Yaws, treatment, 299f
- Yersinia pestis infection, treatment, 315f
- Zalcitabine (ddC), 363f, 369f, 370, **370**
- ZANTAC. *See* Ranitidine
- ZESTRIL. *See* Lisinopril
- Zidovudine (AZT), 363f, 368, **368-369**, 369f
 drug interactions, 339, 367
- Zinc insulin, 255f
- ZITHROMAX. *See* Azithromycin
- ZOCOR. *See* Simvastatin
- Zollinger-Ellison syndrome, treatment, 237, 239
- ZOLOFT. *See* Sertraline
- Zolpidem (AMBIEN), **93**, 93
 therapeutic advantages and disadvantages, 97f
- ZOVIRAX. *See* Acyclovir